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ABSTRACT OF DISSERTATION 
The Relationship Between High Sensitivity C-Reactive Protein, 
Metabolic Syndrome and Exercise. 
by 
Micheline A. Vargas 
Doctor of Public Health Candidate in Preventive Care 
Loma Linda University, Loma Linda University, 2005 
Lee S. Berk, DrPH and Edward K. Fujimoto, DrPH, Co-Chairmen 
Background: It is well known that regular physical activity is associated with 
lower risk of chronic diseases such as diabetes and cardiovascular disease. Physical 
activity is also considered an important determinant of metabolic syndrome. All levels of 
metabolic syndrome, diabetes, and cardiovascular disease are thought tO involve 
inflammation. Physical activity may reduce risk, at least in part, by modifying the 
inflammatory process. Recent studies have demonstrated an inverse relationship between 
inflammatory markers, such as high sensitivity C-reactive protein (hs-CRP), and physical 
activity. Elevated hs-CRP appears to be an independent predictor of both CVD and 
diabetes. Recent evidence also suggests that hs-CRP is positively associated with all 
metabolic syndrome characteristics: low high density lipoprotein (HDL), 
hypertriglyeridemia, hypertension, obesity, and abnormal glucose. 
Purpose: The purpose of this study was to examine the relationship between hs-
CRP, metabolic syndrome and physical activity. Understanding this relationship will 
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provide insight into the potential of physical activity as a therapeutic option to reduce 
cardiovascular disease risk. 
Methodology: This study relied on a cross-sectional, retrospective analysis of an 
archival database from the Center for Health Promotion (CHP). Study participants were 
obtained from a pool of 1,072 men and women patients at the Center of Health Promotion 
(CHP) at Loma Linda University. Of the 1,072 pool, 173 individuals met the inclusion 
criteria and were the subjects of the study. Any missing data variables were imputed 
using the maximum likelihood method (EM) in SYSTAT version 10; SPSS02000. The 
distribution of hs-CRP, the dependent variable of greatest interest, was positively skewed. 
Therefore, a log transformation was applied to hs-CRP values for all analyses. Simple 
regression/correlation analysis was used to evaluate the relationships between log (CRP) 
and each of the relevant variables: VO2max (ml•kg-1•min-1), metabolic syndrome, and the 
physical activity status. The following relationships were explored: (1) hs-CRP and 
metabolic syndrome characteristics, (2) hs-CRP and VO2max, (3) VO2max and metabolic 
syndrome characteristics, and (4) VO2max and physical activity status. Pearson Chi-
square analysis was used to determine if a threshold level of physical activity was 
associated with hs-CRP changes. 
Results: Hs-CRP increased linearly with the number of metabolic syndrome 
characteristics (p = 0.00022). Inverse associations were found between hs-CRP and 
VO2max (p = 0.00008) and between VO2max and the number of metabolic syndrome 
criteria (p = 0.00004). VO2max was positively associated with PA (p = 0.00000). 
Subjects engaging in 2-3 hours of PA per week had hs-CRP levels < 2.5 mg/L (p = 
0.01817). 
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Conclusions: Physical activity may reduce risk by modifying the inflammatory 
process. We found that hs-CRP and metabolic syndrome severity were reduced in those 
with a higher cardiorespiratory fitness level. These associations are suggested 
mechanisms by which cardiorespiratory fitness reduces the risk of CVD and diabetes. 
Our findings support physical activity recommendations set forth by both the Surgeon 
General and the American College of Sports Medicine. This study was also in support of 
recommendations set forth by the ATP-III report to use physical activity as first-line 
therapy for the management of metabolic syndrome. 
Significance to Preventive Care: Preventive Care Specialists often prescribe 
physical activity as a way of reducing chronic diseases such as cardiovascular disease and 
diabetes. Reducing hs-CRP via regular exercise may be an intervention by which 
exercise reduces risk of chronic disease. This study strengths the argument that regular 
physical activity reduces inflammation and metabolic syndrome risk factors thereby 
providing protection against the number one killer in the U.S., cardiovascular disease. 
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CHAPTER 1 
INTRODUCTION 
A. Statement of the Problem 
It is well known that inflammation is involved in mediating all stages of the 
atherosclerotic disease process (Pearson et al., 2003; Libby, Ridker, & Maseri, 2002). 
Hence, markers of inflammation have been examined as potential tools in the prediction 
of cardiovascular events. Of these markers, the acute-phase reactant, high sensitivity C-
reactive protein (hs-CRP), has generated significant interest (Szmitko et al., 2003). 
Emerging evidence suggests that hs-CRP is one of the strongest independent predictors of 
cardiovascular events (Szmitko et al., 2003; Yeh & Willerson, 2003). According to 
LaMonte et al. (2002), elevated hs-CRP is associated with a 2 to 5-fold increase in 
cardiovascular event risk. 
Although hs-CRP has been considered only a biomarker, recent evidence suggests 
that it may directly promote atherosclerosis. According to Szmitko et al. (2003), hs-CRP 
provokes inflammation and endothelial dysfunction. It appears to reduce transcription of 
endothelial nitric oxide synthase (eNOS), which leads to a diminished release of nitric 
oxide (NO). This is turn reduces protection against vascular injury and inflammation. 
Hs-CRP causes further disruption to endothelial homeostasis by stimulating the release of 
endothelin-1 (ET-1) and interleukin (IL)-6, by upregulating adhesion molecules 
(intracellular adhesion molecule-1, vascular cell adhesion molecule-1, selectins), and by 
stimulating the chemokine monocyte chemoattractant protein-1 (MCP-1). Hs-CRP also 
promotes foam cell formation by facilitating LDL uptake by macrophages (Szmitko et al., 
2003; Yeh & Willerson, 2003). Preliminary observations from Szmitko et al. (2003) also 
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indicate that hs-CRP up-regulates nuclear factor KappaB (NF- KB), which facilitates 
transcription of several proatherosclerotic genes. Hs-CRPs proatherogenic effects extend 
beyond the endothelium to the vascular smooth muscle (VSM). In concentrations known 
to predict cardiovascular events, hs-CRP demonstrates up-regulation of angiotensin-type 
1 receptors (ATi-R) in vascular SMCs. This augments VSM proliferation, migration, 
reactive oxygen species (ROS) production, and restenosis (Szmitko et al., 2003). 
Observational studies have provided evidence that physical inactivity and low 
cardiorespiratory fitness predict atherosclerotic cardiovascular disease (Blair et al., 1996; 
Ekelund et al., 1988; Lakka et al., 1994, Laukkanen et al., 2001; Lee, Blair, & Jackson, 
1999; Sandvik et al., 1993), while regular physical activity is associated with lower risk 
of coronary heart disease, stroke, and cardiovascular mortality (Erikssen et al. 1998). 
Physical activity may reduce risk, at least in part, by modifying the inflammatory process 
and reducing endothelial dysfunction. Recent studies have demonstrated an inverse 
relationship between inflammatory markers, such as hs-CRP, and physical activity 
(Geffken et al., 2001; Rawsen et al., 2003). Higher levels of hs-CRP have also been 
associated with obesity and insulin resistance, while physical activity has been associated 
with lesser degrees of obesity and insulin resistance. Based on these findings many 
researchers have speculated that physical activity may be associated with lower levels of 
inflammation via its inverse relationship with obesity and insulin resistance (LaMonte et 
al., 2002). Other researchers believe that physical activity reduces hs-CRP independently 
(Rawson et al., 2003). 
Relatively few studies have examined the effects of physical activity on 
inflammatory markers and results are conflicting (Geffken et al., 2001; Smith et al., 1999; 
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Rawsen et al., 2003). This may be due in part to research design. Several of the studies 
had an inadequate number of participants and others failed to adjust for body composition 
and other confounding variables. According to Pearson et al. (2003) many variables are 
associated with hs-CRP levels. Elevated body fat mass, weight loss, elevated blood 
pressure, cigarette smoking, metabolic syndrome, diabetes, low HDL cholesterol, high 
triglycerides, gender, age, and increased physical activity all appear to influence hs-CRP. 
More research is needed to assess the relationship between hs-CRP, metabolic 
syndrome and physical activity. Questions remain regarding: (1) the relationship 
between cardiorespiratory fitness level and hs-CRP, (2) the threshold level of physical 
activity that is associated with changes in hs-CRP, (3) the type of physical activity 
needed to reduce hs-CRP, (3) the association between hs-CRP, metabolic syndrome and 
cardiorespiratory fitness level, and (4) whether the associations seen between physical 
activity and lowered inflammatory markers is mediated by reduced body fat. 
B. Purpose of the Study 
The purpose of this study was to examine the relationship between hs-CRP, 
metabolic syndrome and physical activity. Understanding this relationship will provide 
insight into the potential of physical activity as a therapeutic option to reduce 
cardiovascular disease risk. This study relied on a cross-sectional, retrospective analysis 
of an archival database from the Center for Health Promotion (CHP). Study participants 
were obtained from a pool of 1,072 men and women patients at the Center of Health 
Promotion (CHP) at Loma Linda University. Of the 1,072 pool, 173 individuals met the 
inclusion criteria and were the subjects of the study. Any missing data variables were 
imputed using the maximum likelihood method (EM) in SYSTAT version 10; 
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SPSS©2000. Because the percent body fat variable required over 100 imputations to fill 
in all of the missing data it was not used in any analyses. The distribution of hs-CRP, the 
dependent variable of greatest interest, was positively skewed. Therefore, a log 
transformation was applied to hs-CRP values for all analyses. Simple 
regression/correlation analysis was used to evaluate the relationships between log(CRP) 
and each of the relevant variables: VO2max (ml•kg-1•min-1), metabolic syndrome, and the 
physical activity status. The following relationships were explored: (1) hs-CRP and 
metabolic syndrome characteristics, (2) hs-CRP and VO2max, (3) VO2max and metabolic 
syndrome characteristics, and (4) VO2max and physical activity status. Pearson Chi-
square analysis was used to determine if a threshold level of physical activity was 
associated with hs-CRP changes. Understanding these relationships provides insight into 
the potential of physical activity as a therapeutic option to reduce cardiovascular disease 
risk (Church et al., 2002). 
C. Research Questions 
1. What is the relationship between fitness level and hs-CRP? 
2. What is the relationship between hs-CRP, the metabolic syndrome and 
cardiorespiratory fitness? 
3. Is there a threshold level of physical activity that is associated with changes in hs- 
CRP? 
D. Mechanisms 
Several theories exist as to how regular physical activity reduces hs-CRP and the 
inflammatory process. Mattusch et al. (2000) suggested that hs-CRP levels were 
reduced, at least in part, due to enhanced antioxidative defense mechanisms seen after 
regular exercise training. It has been reported that well trained athletes have increased 
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activity in muscular and erythrocytic antioxidative enzymes. Animal studies have also 
shown improved antioxidant defense mechanisms after exercise training. It may be that 
enhanced antioxidative protection reduces the production of IL-6 and other cytokines in 
the exercising muscle. 
Church et al. (2002) also proposed interleukins as a potential pathway. Evidence 
suggests that tumor necrosis factor-a (TNF-a) and IL-6 are involved in hs-CRP 
production. TNF-a stimulates the production of IL-6 and IL-6 stimulates the production 
of hs-CRP. Regular exercise training appears to lower basal plasma interleukin 
concentrations and TNF-a. The release of TNF-a and IL-6 is augmented by the 
downregulation of sympathetic stimulation via regular physical activity. Reductions in 
TNF- a and IL-6 have been found independently of weight loss, hence, TNF-a and IL-6 
may be responsible for reduced hs-CRP in fit individuals (Church et al., 2002). 
Smith et al. (1999) found that exercise reduced TNF- a. These researchers 
examined the possibility that long-term exercise could favorably alter the production of 
cytokines with atherogenic and atheroprotective properties. Cytokines with atherogenic 
properties include IL-1, TNF-a, and interferon-y (IFN-y). Cytokines with 
atheroprotective properties include IL-4, IL-10, and transforming growth factor beta 
(TGF-B). Smith et al. (1999) measured the effects of exercise on the production of these 
cytokines along with serum levels of hs-CRP. Following six months of moderate 
intensity training proatherosclerotic cytokine production was attenuated, while 
atheroprotective cytokine production was increased. These changes were proportionate 
to the time participants spent performing repetitive lower-body exercises, suggesting a 
dose-response relationship. A reduction in hs-CRP accompanied the changes in immune 
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cell function. This could indicate a systemic decrease in the production of both IL-1 and 
TNF-a. These alterations were seen independently of aspirin or other medication use, 
dieting, weight loss, and smoking cessation. In addition to reductions in IL-6 and TNF-a, 
Smith et al. (1999) found a significant attenuating effect on IFN-y. IFN-y and TNF-a 
have been identified in early and advanced atherosclerotic lesions. They appear to 
activate endothelial cells, monocytes, macrophages, and smooth muscle cells, hence they 
contribute to leukocyte recruitment, endothelial cell procoagulant activity, LDL 
oxidation, and foam cell formation. Therefore, reducing these and other 
proatherosclerotic cytokines via regular exercise is of value for those persons at risk of 
developing cardiovascular disease (Smith et al., 1999). 
Several theories exist as to how exercise reduces hs-CRP. These potential 
mechanisms along with a reduction in traditional risk factors, such as hypertension, 
elevated cholesterol, elevated triglycerides, impaired glucose tolerance, and diabetes 
mellitus likely lead to a reduction in hs-CRP and cardiovascular disease. Figure 1 shows 





less evidence 	more evidence 
Figure 1. Potential mechanisms by which exercise reduces hs-CRP and 
Cardiovascular Disease (CVD). IL-6 = interleukin-6, TNF-a = tumor necrosis factor-a, 
CRP = c-reactive protein, HTN = hypertension, CH = cholesterol, TG = triglyceride, IGT 
= impaired glucose tolerance, DM = diabetes mellitus, NO = nitric oxide, ET-1 = 
endothilin-1, ICAM = intracellular adhesion molecule, VCAM = vascular cell adhesion 
molecule, ATIR = angiotensin type-1 receptor, MCP-1 = monocyte chemoattractant 
protein-1, NFKI3 = nuclear factor KB. 
E. Significance to Preventive Care 
Preventive Care Specialists often prescribe physical activity as a way of reducing 
chronic diseases such as cardiovascular disease and diabetes. Physical activity provides 
protection to the cardiovascular system via multiple mechanisms: (1) increased 
dimension of coronary arteries; (2) improved coagulation system; (3) increased stroke 
volume, and (4) increased maximal oxygen uptake (Geffken et al. 2000). Reducing 
inflammation (i.e. hs-CRP) via regular exercise may be yet another mechanism by which 
exercise decreases risk of chronic disease. This study investigates the impact of regular 
physical activity on the inflammatory process and cardiovascular disease risk to confirm 
and extend available data. Hence, it will strengthen the argument for regular physical 
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activity and support the Surgeon General's recommendation to include a moderate 
amount of physical activity on most, if not all days of the week. This study will also 
likely support the theory that regular physical activity, regardless of body fat mass, 
reduces risk of chronic disease. This could send yet another public health message. Even 
low to moderate amounts of regular physical activity provide protection from the number 
one killer in the U.S., cardiovascular disease. 
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CHAPTER 2 
REVIEW OF LITERATURE 
A. Overview 
Atherosclerosis was formerly considered a mere lipid storage disease when in 
actuality it involves an ongoing inflammatory response with the endothelium being the 
primary site of dysfunction. Advances in basic and experimental science have 
established that inflammation is involved in mediating all stages of this disease from 
initiation through progression and, ultimately, to atherosclerotic plaque complications 
(Pearson et al., 2003; Libby, Ridker, & Maseri, 2002). Several markers of the 
inflammatory cascade have been examined as potential tools in the prediction of 
cardiovascular events. Among them are markers of systemic inflammation produced in 
the liver, such as high sensitivity C-reactive protein (hs-CRP) and serum amyloid A 
(SAA); cytokines such as interleukin-6 (IL-6) and tumor necrosis factor-a (TNF-a); and 
adhesion molecules such as vascular cell adhesion molecule 1(VCAM-1) and 
intercellular adhesion molecule-1 (ICAM-1). Of these markers, the acute-phase reactant, 
hs-CRP, has generated significant interest (Szmitko et al., 2003). Emerging evidence 
suggests that hs-CRP is one of the strongest independent predictors of cardiovascular 
events (Szmitko et al., 2003; Yeh & Willerson, 2003). Ridker, Hennekens, Burning, and 
Rifai (2000) found that hs-CRP was better than low-density lipoprotein (LDL) 
cholesterol at predicting cardiovascular events and according to LaMonte et al. (2002) 
elevated hs-CRP is associated with a 2 to 5-fold increase in cardiovascular event risk. 
Although, once thought to act only as a biomarker new evidence is showing that hs-CRP 
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plays a more functional role in the atherosclerotic disease process. This new information 
is profound and will likely change the way we screen and manage patients (Yeh & 
Willerson, 2003). 
It is well known that regular physical activity reduces the risk of cardiovascular 
disease and recent studies have found an association between physical activity and hs-
CRP. Greater understanding of this relationship may provide insight into the potential of 
exercise as a therapeutic option to reduce hs-CRP (Church et al., 2002). At this time 
there are no firm conclusions as to how exercise reduces the inflammatory process or hs-
CRP. Only a handful of studies have examined the effects of exercise on inflammatory 
markers and of those many have presented conflicting results. This may be due in part to 
research design. Many lack either a reliable measure of regular physical activity, 
adjustments for body weight and other confounding variables, or an adequate number of 
participants. The cohorts used also differ significantly making it difficult to compare 
results. 
This chapter will review epidemiological and experimental evidence regarding the 
role of hs-CRP in primary prevention, inflammation in atherosclerosis, the functional role 
of hs-CRP in the atherosclerosis process, and the effects of exercise on hs-CRP. Studies 
for this review were identified using computer searches of Medline, PubMed, and 
prominent peer reviewed journals. 
B. Hs-CRP Use in Primary Prevention 
Emerging evidence suggests that hs-CRP is one of the strongest independent 
predictors of cardiovascular events. It appears to be an even stronger predictor than LDL 
cholesterol (Yeh & Willerson, 2003) and it adds prognostic value to the Framingham risk 
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assessment score and all levels of the metabolic syndrome (Szmitko et al., 2003; Ridker, 
2003). In the Framingham Heart Study, coronary heart disease occurred in 
approximately one third of the individuals with total cholesterol less than 200 mg/dL 
(Castelli, 1996). 
According to Ridker (2003), over a dozen prospective epidemiological studies 
have found a single, non-fasting measure of hs-CRP to be a strong predictor of 
cardiovascular events in individuals with no prior history of cardiovascular disease. 
Initial data from the Multiple Risk Factor Interventional Trial (MRFIT) (Kuller, Tracey, 
Shaten, Meilahn, 1996), the Women's Health Study (Ridker, Hennekens, Buring, and 
Rifai, 2000), the Rural Health Promotion Project (Tracy, Lemaitre, Psaty, Ives, Evans, 
Cushman, Meilahn, and Kuller, 1997), the NIH-funded Coronary Heart Study (Tracy et 
al., 1997), the Physicians' Health Study (Ridker, Cushman, Stampfer, Tracy, and 
Hennekens, 1997; Ridker, Cushman, Stampfer, Tracy, and Hennekens, 1998a), the 
MONICA-Augsburg Cohort Study (Koenig, Sund, Frohlich, Fischer, Lowel, Doring, 
Hutchinson, Pepys, 1999), and the Helsinki Heart Study (Roivainen, Viik-Kajander, 
Fischer, Lowel, Doring, Hutchinson, et al., 2000) are just a few of the prospective studies 
conducted in the United States and Europe that have found an association between 
baseline hs-CRP levels and risk of first cardiovascular event. Hs-CRP's strong predictive 
value may be partially explained by its long-term stability during storage. One study 
recently found that hs-CRP was a strong predictor of risk even 20 years after the initial 
blood samples were acquired (Ridker, 2003). Hs-CRP has a long half-life, it lacks 
diurnal variation, and it lacks age and sex dependence (Yeh & Willerson, 2003). 
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Simple clinical cut points have been established from event-free survival data 
allowing clinicians to interpret hs-CRP levels. An hs-CRP assay, such as Dade Behring, 
is needed to detect levels within the normal range (low grade levels). Hs-CRP predicts 
cardiovascular events within this normal range (Rifai, Tracy, and Ridker, 1999). 
Standard CRP tests determine levels that are increased several hundred-fold if not a 
thousand-fold during acute infection and tissue injury and are not able to detect low grade 
levels of CRP. Using the hs-CRP assays we can categorize patients as low (<1 mg/L), 
moderate (1-3 mg/L), or high risk (3-10 mg/L) for future cardiovascular events. Levels 
exceeding 10 mg/L may indicate a possible acute phase response. In this case, the test 
should be repeated within a few weeks (Ridker, 2003; Yeh & Willerson, 2003). 
In addition to hs-CRP, other biomarkers have been shown to predict myocardial 
infarction and stroke. Sophisticated methods have been utilized to measure adhesion 
molecules, cytokine activity, and immunologic functions (i.e. ICAM-1, IL-6). 
Unfortunately, measures of these biomarkers are often inappropriate for clinical use: the 
assays used are often inappropriate for routine clinical use, the protein being measured 
has a short half-life, or the marker has not been standardized (Ridker, 2003). Hs-CRP on 
the other hand, has a standardized assay and is stable. It has a half life of about 18-20 
hours, partly due to its pentraxin structure. This allows the measure to be made from 
either fresh or frozen plasma. 
The Women's Health Study compared ten biomarkers for vascular disease 
(Ridker et al, 2000). The researchers compared lipoprotein(a), homocysteine, IL-6, 
soluble ICAM-1, serum amyloid A (SAA), total cholesterol (TC), LDL, Apolipoprotein 
B, TC to high density lipoprotein cholesterol (HDL) ratio, hs-CRP, hs-CRP plus TC:HDL 
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ratio. Interestingly, they found that SAA and soluble ICAM-1 were better risk markers 
than TC or LDL. The best lipid marker was the TC:HDL ratio, which is consistent with 
many epidemiological studies. Hs-CRP was, however, the best predictor of risk. Hs-CRP 
screening, on its own, was associated with a 4.4-fold increase in vascular risk in the 
study's participants. But, the best overall risk estimate was found when hs-CRP was 
combined with TC:HDL ratio (Ridker et al., 2000). In an analysis from the Physicians' 
Health Study, Ridker, Glynn, and Hennekens, (1998b) found an interaction between hs-
CRP and TC:HDL ratio. Hence, using both these parameters may do a better job of 
predicting risk than using either alone. 
The Women's Health Study prospectively examined the predictive value of LDL 
and hs-CRP in 27,939 postmenopausal women for approximately eight years. The 
researchers found that hs-CRP was a better predictor of cardiovascular event risk than 
LDL (Ridker et al. 2002). Even after adjusting for all Framingham risk score 
components, hs-CRP appeared to be an independent risk factor for stroke, myocardial 
infarction, and cardiovascular mortality. Women with low LDL levels (<123.7 mg/dL), 
but high hs-CRP values were at higher risk for cardiovascular events than the women 
with higher LDL (>123.7) levels, but low hs-CRP values (Ridker et al., 2000). Hence, 
the addition of hs-CRP to traditional cholesterol testing may improve risk prediction, but 
might also improve compliance with preventive approaches. According to Ridker 
(2003), it is well established that absolute risk perceived by an individual is directly 
related to compliance with lifestyle recommendations. Hs-CRP evaluation may be useful 
for this reason alone. 
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In addition to its ability to add predictive value to traditional lipid screening, hs-
CRP also adds prognostic value to all levels of the metabolic syndrome (Szmitko et al., 
2003; Ridker, 2003). Inflammation, not elevated LDL, plays a major role in almost all 
processes associated with the metabolic syndrome. Ridker (2003) stated that hs-CRP 
levels are associated with triglycerides, obesity, blood pressure, and fasting glucose, all of 
which are components of the Adult Treatment Panel III (ATP III) metabolic syndrome 
definition. Ridker (2003) examined the possible interrelationships between the metabolic 
syndrome, hs-CRP, and cardiovascular events in participants in the Women's Health 
Study (n = 14,719). The women were aged 45 and older and apparently healthy with no 
prior history of cardiovascular disease or cancer and did not have diabetes at baseline. 
The participants had also 'complete data for all components of the metabolic syndrome. 
Ridker (2003) found a significant (p-trend <0.0001) linear relationship between the 
number of metabolic syndrome criteria and hs-CRP level (0.68 mg/L for women who met 
no criteria of the metabolic syndrome to 5.75 mg/L for women who met all 5 criteria). 
Festa, D'Agostino, Howard, Mykkanen, Tracy, and Haffner (2000) also found an 
association between the metabolic syndrome and hs-CRP. In the Insulin Resistance 
Atherosclerosis Study (IRAS), Festa et al. (2000) found that hs-CRP levels in non-
diabetic subjects increased in a monotonic fashion as the number of metabolic disorders 
increases. According to Ridker (2003), insulin sensitivity and impaired fibrinolysis, 
which are additional factors associated with the metabolic syndrome also appear to be 
associated with hs-CRP. Ridker (2003) also stated that several prospective studies have 
found hs-CRP to predict type 2 diabetes. Risk for developing type 2 diabetes appears to 
increase 4 to 6-fold in individuals with hs-CRP levels >3mg/L. These studies further 
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suggest inflammation, atherosclerosis, and diabetes as interconnected disorders of the 
innate immune system. 
Studies conducted in both the U.S. and Europe have consistently found a 
relationship between an individual's baseline hs-CRP level and future vascular risk. In 
most cases this has been seen independent of cholesterol levels, blood pressure, age, 
smoking, and diabetes. Effects are seen in men and women, middle age and elderly, 
those with low absolute risk and those with high absolute risk for vascular events 
(Ridker, 2003). Although, hs-CRP appears to be associated with an increased risk for 
cardiovascular disease controversy surrounds the role hs-CRP actually plays in the 
atherosclerotic disease process. In order to further understand hs-CRPs role as an 
inflammatory biomarker or a possible risk factor, we must first understand the link 
between inflammation, endothelial dysfunction, and atherosclerosis. 
C. Endothelial Dysfunction, Inflammation, and Atherosclerosis 
The role of inflammation has become a well established theory in describing the 
atherosclerotic disease process (Pearson et al., 2003; Libby, Ridker, and Maseri et al., 
2002). From a pathological standpoint all stages from initiation to plaque rupture are 
considered to be an inflammatory response to injury. The traditional triggers that 
promote atherogenesis include, cigarette smoking, atherogenic lipoproteins, hypertension, 
and hyperglycemia. These triggers encourage a number of noxious stimuli that elicit 
secretion of both leukocyte soluble adhesion molecules, which facilitate monocyte 
attachment to the endothelium, and chemotactic factors, which enable the monocytes to 
migrate into the subendothelial space (Pearson et al., 2003; Libby, Ridker, and Maseri et 
al., 2002). 
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Endothelial injury results in "dysfunction". According to Szmitko et al. (2003) 
dysfunction involves an imbalance in endothelium-derived relaxing factors, such as nitric 
oxide (NO) and contracting factors, such as endothelin-1 (ET-1), angiotensin, and 
oxidants. The imbalance between endothelial-derived vasodilating and vasoconstricting 
substances impairs regulation of vascular tone. As production or availability of NO is 
diminished, its ability to protect against vascular injury, inflammation, and thrombosis is 
diminished. Normally NO inhibits leukocyte adhesion, helps maintain non-proliferative 
vascular smooth muscle, and limits platelet aggregation (Sztnitko et al., 2003). 
Unfortunately, CVD risk factors, such as hypercholesterolemia, hypertension and 
diabetes, reduce endogenous defenses of the vascular endothelium and it begins to break 
down. Hypercholesterolemia enhances blood leukocyte attachment to the endothelium 
(Szmitko et al., 2003). This may lead to an increase in the amount of low-density 
lipoproteins (LDL) that becomes oxidized. Oxidized LDL (oxLDL) activate and change 
the biological characteristics of the endothelium reducing intracellular NO concentrations 
(Szmitko et al., 2003). Angiotensin II, a potent vasoconstrictor associated with 
hypertension, also has several negative effects. Angiotensin II, according to Wang et al. 
(2003), is a key bioactive factor involved in the atherosclerotic disease process. It 
inhibits NO action, elicits reactive oxygen species (ROS), increases IL-6 and monocyte-
chemoaftractant protein-1 (MCP-1), and up-regulated VCAM-1 on the endothelium 
(Szmitko et al., 2003). According to Szmitko et al. (2003) newer risk factors such as hs-
CRP also appear to promote endothelial dysfunction. Hs-CRP quenches the production 
of NO and diminishes its bioactivity. All these endothelial alterations enhance 
inflammation (Szmitko et al., 2003). 
16 
Once endothelial cells undergo inflammatory activation, areas of the arterial 
endothelium start to express selective adhesion molecules on their surface (Charo, 1992; 
Libby, Ridker, and Maseri et al., 2002; Szmitko et al., 2003). These adhesion molecules 
bind to various classes of leukocytes (Libby, Ridker, and Maseri et al., 2002). Research 
has identified a number of vascular endothelial adhesion molecules that can mediate 
leukocyte adhesion to the endothelium in a selective manner. According to Luscinskas & 
Gimbrone (1996) the primary examples are from four gene families: 1) the selectins (E-
P-and L-selectin); 2) the itnmunoglobulin family [ICAM-1, -2, and -3; VCAM-1; 
platelet-endothelial cell adhesion molecule (PECAM-1)1; 3) the integrins (B1- and B2-
integrins); and 4) mucin-like adhesion molecules [P-selectin glycoprotein ligand-1 
(PSCG-1)]. Once activated, endothelial cells can also synthesize an array of leukocyte 
chemoattractants, such as members of the chemokine gene family [MCP-1 and 
interleukin-8 (IL-8)], platelet-activating factor (PAF), and leukotriene B4 (LTB4) 
(Luscinskas & Gimbrone, 1996; De Caterina et al., 2000). Chemoattractants such as 
LTB4  and PAF act broadly on neutrophils, eosinophils, basophils, and monocytes, 
whereas others such as MCP-1 and IL-8 are selective for leukocyte subsets (De Caterina 
et al., 2000). Multiple receptor-ligand pairs appear to function in a sequential manner (an 
adhesion cascade) to allow the initial interactions of leukocytes with the endothelial 
lining. This initial interaction is called phase I or the rolling phase. The initial rolling 
interactions are weak and reversible unless the leukocytes are activated to undergo stable 
adhesion. This stable adhesion is considered phase II or the arrest and spreading phase. 
During the rolling interval, chemoattractants derived from the endothelium, such as 
MCP-1 and IL-8, appear to critically affect adhesion of mononuclear leukocytes by 
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triggering the activation of Bl- and B2-integrin (Devaraj, Kumaresan, and halal, 2003; 
Luscinskas & Gimbrone, 1996, Wang et al., 2004). Once the integrins are activated a 
dramatic increase in monocyte adhesivness is seen, presumably via binding to ligands, 
such as ICAM-1 and -2 and VCAM-1. This results in stable arrest (phase II). The 
monocyte flattens and extends pseudopods toward the intercellular junctions between 
neighboring endothelial cells. The monocyte ultimately transmigrates through the 
endothelial junctions into the extravascular space (phase III, transmigration). PECAM-1 
is involved in this last step, along with B 1- and B2-integrins (Charo, 1992; Luscinskas & 
Gimbrone, 1996). This entire process takes place within minutes for monocytes, but 
significantly longer for T cells. Monocytes and lymphocytes can directly influence the 
endothelium and each other once inside the interstitial space by secreting growth factors, 
chemotactic substances, and cytokines such as interleukin-4 (IL-4), interferon-y (IFN-y), 
interleukin-10 (IL-10), interleukin-2 (IL-2), and interleukin-12 (IL-12) (Luscinskas & 
Gimbrone, 1996). 
Blood-derived inflammatory cells participate in and perpetuate a local 
inflammatory response once they have resided in the arterial wall (Libby, Ridker, and 
Maseri et al., 2002). Native LDL may be oxidized by resident vascular cells, such as 
endothelial cells, smooth-muscle cells, and macrophages, after it becomes trapped in the 
subendothelial space. The oxLDL can stimulate monocyte chemotaxis along with 
endothelial dysfunction and injury (Ross, 1999). Endothelial cells are activated by the 
oxLDL to express MCP-1, which attracts monocytes into the subendothelial space from 
the vessel lumen (Navab et al., 1991). Once inside the intima monocytes differentiate 
into macrophages. Macrophages begin to express scavenger receptors, such as SR-A, 
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CD36, and LOX-1, which allows them to ingest the oxLDL and become foam cells 
(Szmitko et al., 2003). Macrophage colony-stimulating factor (M-CSF) along with MCP-
1 contributes to the monocyte differentiating into the macrophage foam cell. T-cells also 
produce inflammatory cytokines (INF-y and TNF-B), which in turn stimulate 
macrophages, vascular endothelial cells, and smooth muscle cells (SMCs). 
As the process continues, macrophages and foam cells release fibrogenic 
mediators (i.e. peptide growth factors). These mediators can promote SMC replication 
and contribute to proliferation and production of dense extracellular matrix, creating a 
fibrous cap (Libby, Ridker, and Maseri et al. 2002; Ross, 1999). IL-8, which is present in 
macrophage dense areas of the atheroma, can also induce proliferation and migration of 
SMC (Devaraj, Kumaresan, and Jialal, 2003). The vascular smooth muscle cells 
(VSMC) that accumulate in the intima play a key role in the development of the arterial 
lesion. These cells synthesize collagen that stabilize the fibrous cap. However, as the 
lesion progresses VSMC apoptosis occurs, contributing to plaque vulnerability. 
Blaschke et al. (2004) found that hs-CRP induced VSMC apoptosis in cultured 
human VSMCs via up-regulation of growth arrest-and DNA damage- inducible gene 153 
(GADD153) mRNA expression. According to Blaschke et al. (2004) GADD153 is 
involved in growth arrest and apoptosis in both vascular and non-vascular cells. Using 
immunohistochemistry, Blaschke et al. (2004) were able to identify hs-CRP deposition in 
the deeper parts of the intima adjacent to the media and in the plaque shoulder region in a 
fibrous cap atheroma. They were also able to identify VSMCs as hs-CRP containing 
cells with a-Smooth muscle actin stain. 
19 
As the atherosclerotic disease process continues the plaque becomes more 
unstable. Foam cells and macrophages produce metalloprotienases that contribute to 
matrix degradation. Hence, they contribute to both growth of the lesion and plaque 
instability. IL-8 also contributes to the breakdown of the fibrous cap as it begins to 
inhibit tissue inhibitor of metalloproteinase (TIMP) (Devaraj, Kumaresan, and Jialal, 
2003). As the proteolytic enzymes degrade the collagen in the fibrous cap, it becomes 
thin, weak, and susceptible to rupture (Libby, Ridker, and Maseri et al., 2002). T-
lymphocytes are also involved in the degradation of the fibrous cap. They produce INF-
y, which can halt the synthesis of collagen by the SMC, thereby limiting the renewal of 
collagen. 
The thinning fibrous cap is now more vulnerable to rupture (Ross, 1999). Once 
the plaque has been disrupted excessive apoptosis of the VSMCs can increase 
thrombogenicity. The VSMCs produce active thrombin, which activates platelet 
adherence (Devaraj, Kumaresan, and halal, 2003). Macrophages produce tissue factor, 
which is a major procoagulant and can trigger thrombosis. Thrombus formation can lead 
to vessel occlusion and trigger a cardiovascular event. 
It has been thought for some time that inflammatory mediators are important 
regulators of the atherosclerotic disease process (Libby, Ridker, and Maseri et al., 2002), 
but only recent evidence has begun to demonstrate the functional role of hs-CRP. Hs-
CRP is now emerging to be more than just a biomarker. It is being examined for its 
functional role in the atherosclerotic disease process. 
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D. Hs-CRP, Atherosclerotic Biomarker or Contributor 
Recent evidence suggests that hs-CRP may directly promote atherosclerosis. 
Traditionally, it has been thought that hepatocytes, during the acute-phase response, 
produced hs-CRP exclusively. Recent evidence, however, suggests that hs-CRP is being 
produced by the atherosclerotic arteries themselves. Calabro, Willerson, and Yeh (2003) 
found that human coronary artery SMCs could produce hs-CRP when incubated with 
inflammatory cytokines: TNF-a, IL-6, interleukin-1B (IL-1B) or a combination of IL-1B 
and IL-6. Calabro, Willerson, and Yeh (2003) concluded that locally produced hs-CRP 
participated directly in atherogenesis and cardiovascular complications. 
According to Szmitko et al. (2003), hs-CRP provokes inflammation and 
endothelial dysfunction via multiple mechanisms. It appears to reduce transcription of 
endothelial nitric oxide synthase (eNOS) and destabilizes eNOS mRNA, which leads to a 
diminished release of nitric oxide (NO). This is turn reduces protection against vascular 
injury and inflammation. Hs-CRP causes further disruption to endothelial homeostasis 
by stimulating the release of ET-1 and IL-6, by up-regulating adhesion molecules 
(ICAM-1, VCAM-1, selectins), and by stimulating MCP-1. Hs-CRP also appears to 
increase the expression of plasminogen activator inhibitor-1 (PAI-1), a serine protease 
inhibitor. PAT-1 inhibits tissue plasminogen activator (tPA), thereby regulating 
fibrinolysis in atherothrombosis. (L. Li, Roumeliotis, Sawamura, and Renier, 2004; Wang 
et al. 2004). Nuclear factor-KB (NF- KB), a key transcription factor involved in 
controlling gene expression concerning the inflammatory response, also appears to be 
affected by hs-CRP (J. Li, Fang, Chen, Chen, and Lee, 2004). Preliminary observations 
from Szmitko et al. (2003) indicate that hs-CRP up-regulates NF- KB. NF- KB remains 
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inactive in the cytoplasm of monocytes, lymphocytes, smooth muscle cells, and 
endothelial cells, until it is stimulated (Li et al. 2004). Once stimulated NF- KB 
transcriptionally activates several proatherosclerotic genes (Szmitko et al., 2003): IL-1, 
IL-6, IL-8, interferon, TNF-a, endothelial cell adhesion molecule-1 (ECAM-1), ICAM-1, 
and VCAM-1 (Li et al., 2004). Activated NF- KB has been found in the coronary 
vasculature and in atherosclerotic lesions, even in early stages. 
According to Ghanim et al. (2004), an increase in NF- KB in the nucleus and a 
decrease in its inhibitors I KB-a and/or I KB-B describe inflammation at the cellular level. 
Ghanim et al. (2004) examined the proinflammatory state of peripheral blood 
mononuclear cells (MNC) in obese subjects. They found that transcriptional activity was 
increased in IL-6, TNF-a, migration inhibitor factor (MIF), and matrix metalloproteinase-
9 (MMP-9) genes of healthy non-diabetic obese female participants when compared to 
normal-weight controls. This increase in transcriptional activity was reflected by 
increased levels of mRNA, which is consistent with increased binding of intranuclear 
NF- KB. Obese participants had significantly higher (p<0.05) DNA binding of the 
transcriptionally active form of NF- KB (p65/p50) in MNCs compared with lean 
participants. Significant correlations between NF- KB binding and hs-CRP was also seen. 
L. Li, Fang, et al. (2004) also found a positive correlation between serum levels of 
hs-CRP and NF- KB activity. These researchers investigated NF- KB activity in white 
blood cells from patients (n = 33) with coronary heart disease (CHD). Participants with 
unstable angina had an increase in NF- KB activity and elevated hs-CRP levels compared 
to those with stable angina. Li et al. (2004) concluded that hs-CRP and NF- KB are 
useful in detecting vulnerable plaque and unstable angina. 
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Wang et al. (2005), like other researchers (Ghanim et al. 2004; L. Li, Fang et al. 
2004; Szmitko et al., 2003), concluded that hs-CRP can significantly influence vascular 
endothelial gene expression and therefore play a functional role in atherogenesis. In 
order to investigate the effects of hs-CRP on vascular endothelial cell gene expression, 
Wang et al. (2005) incubated human vascular endothelial cells with hs-CRP in 
concentrations ranging from 0-10 ug/ml. They found that eleven genes (IL-8, PAI-1, 
MCP-1, Fibronectin-1, Connexin-43, ZF9, Activin A, EXT1, Cited2, SORL-1, and 
Gravin) increased and six genes (PIN, AnnexinA 1, MAT2A, WRB, RCN1, and TEB4) 
decreased on their mRNA levels. The IL-8 gene was the most significantly up-regulated 
gene, with a 13.6-fold increase. This up-regulation began as early as three hours after 
incubation with hs-CRP and continued for over 24 hours. This is a significant find 
because IL-8 is involved in many aspects of the atherosclerotic disease process. As 
stated by Devaraj, Kumaresan, and halal (2003), IL-8 mediates recruitment and 
transmigration of phagocytes across the endothelium and appears to be a powerful trigger 
for monocyte adhesion to the endothelium. Wang et al. (2005) found that monocyte 
adhesion to the endothelium was enhanced 2-fold (p<0.01) by hs-CRP. They also found 
that the response was partially blocked by an anti-IL-8 antibody. IL-8 is also important 
during later stages of atherogenesis. It is induced by lipid loading of macrophages and is 
found in macrophage-rich areas of human coronary atheroma. It stimulates proliferation 
and migration of VSMCs and inhibits tissue inhibitor of metalloproteinase (TIMP) seen 
during later stages of the disease (Devaraj, Kumaresan, and Jialal, 2003). Hence, IL-8 is 
involved in the building up and breaking down of the atheroma's fibrous cap. 
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Devaraj, Kumaresan, and halal (2003) also found that hs-CRP effected IL-8 
expression and synthesis. Like Wang et al., (2005), Devaraj, Kumaresan, and halal 
(2003) incubated human aortic endothelial cells (HAEC) with hs-CRP. Western blotting 
was used to assay IL-8 protein, and B-actin was used as a loading control. Devaraj, 
Kumaresan, and halal (2003) found that hs-CRP (5 to 50 ug/ml) increased IL-8 protein 
levels in a dose-dependent manner. Incubation with hs-CRP also resulted in a dose-
dependent increase in IL-8 mRNA levels. Actinomycin D, a transcription inhibitor of IL-
8, prevented an increase in IL-8 following incubation with hs-CRP. It would appear from 
these finding that hs-CRP effects IL-8 at the transcriptional level. Therefore, Devaraj, 
Kumaresan, and Jialal, 2003 further investigated the effects of hs-CRP on NF-KB. They 
found that hs-CRP did in fact augment NF-KB activity and that inhibitors of NF-KB 
reversed the up-regulation of IL-8 by hs-CRP significantly 
The induction of IL-8 expression and synthesis via up-regulation of NF-KB 
activity in HAEC found by Devaraj, Kumaresan, and halal (2003) provides additional 
evidence that hs-CRP has atherogenic properties. This information is valuable because it 
provides a possible pathway for risk reduction. Because IL-8 is a key player in 
atherosclerosis, its reduction could potentially reduce risk. Therefore, a reduction in hs-
CRP could possibly decrease risk, at least in part, by reducing IL-8. 
As mentioned previously Wang et al. (2005) found several genes to be down-
regulated following incubation with hs-CRP. One of those genes was PIN, a protein 
inhibitor of neuronal nitic oxide synthase (nNOS). According to Wang et al. (2005), the 
nitric oxide (NO) derived from nNOS is neurotoxic during the initial phase of ischemia. 
Inhibition of nNOS might decrease ischemic injury of neurons after a cerebral vascular 
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accident (CVA). According to Wang et al. (2005), clinical observations support this 
theory. Several studies have found that higher concentrations of hs-CRP predict worse 
outcomes in CVA patients (Di Napoli, Papa, and Bocola, 2001; Winbeck, Poppert, Etgen, 
Conrad, and Sander, 2002). By preventing the down-regulation of PIN, via hs-CRP 
reduction, we may thereby reduce ischemic injury and improve CVA patient outcomes. 
Another mechanism by which hs-CRP provokes endothelial dysfunction is via its 
promotion of foam cell formation. Hs-CRP facilitates oxLDL uptake by macrophages 
(Szmitko et al., 2003; Yeh & Willerson, 2003). It is well known that a crucial step in 
atherogenesis is the unregulated uptake of oxLDL by vascular cells (L. Li, Roumeliotis, 
Sawamura, and Renier, 2004). This uptake causes further activation of the endothelium 
and changes the biological characteristics. A newly identified receptor of oxLDL is 
endothelial lectin-like oxidized LDL receptor-1 (LOX-1). Accumulating evidence 
suggests uptake via LOX-1 may also induce endothelial dysfunction. The binding of 
oxLDL to endothelial LOX-1 decreases NO production, generates superoxide anions, and 
activates NF- KB, all of which contribute to endothelial dysfunction (L. Li et al., 2004). 
L. Li et al. (2004) investigated the effects of hs-CRP on LOX-1 expression, 
monocyte adhesion to the endothelium, and endothelial uptake of oxLDL. They 
incubated human aortic endothelial cells (HAECs) with hs-CRP. Hs-CRP, in 
concentration of just 5 ug/mL, enhanced LOX-1 mRNA levels. Concentrations between 
10-25 ug/mL produced maximal effects. L. Li, Roumeliotis et al. (2004) also found that, 
through LOX-1, hs-CRP increased monocyte adhesion and uptake of oxLDL by the 
endothelial cells. They concluded that increased LOX-1 expression via hs-CRP was 
another mechanism by which hs-CRP promotes endothelial dysfunction. 
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Hs-CRPs proatherogenic effects extend beyond the endothelium to the VSMC. 
Hs-CRP appears to stimulate VSMC, at least in part, by activating NF- KB (J. Li, Wang, 
Huang, Xue, and Li, 2005) and by up-regulating angiotensin-type 1 receptors (ATi-R) 
(Szmitko et al. 2003; Wang et al. 2003). In concentrations known to predict 
cardiovascular events, hs-CRP demonstrates up-regulation of ATi-R in VSMC. ATi-R 
mediates the majority of angiotensin II effects. ATi-R up-regulation augments ROS 
production, restenosis, and VSMC proliferation and migration (Szmitko et al. 2003; 
Wang et al. 2003). Wang et al. (2003) examined the effects of human VSMCs treated 
with human recombinant CRP (0 to100 ug/mL). They found that ATi-R mRNA and 
protein expression were up-regulated. ATi-R number was also increased on VSMCs. 
VSMC migration and proliferation was promoted by hs-CRP and hs-CRP increased 
production of ROS. 
Current research is beginning to support the theory that hs-CRP is more than just 
a biomarker for CVD. Hence, therapies directed at its reduction appear to be valuable. 
Therapies, such as aspirin or statin-class medications, have been shown to reduce hs-
CRP. Obisesan et al. (2004) stated that statin therapy has been shown to decrease hs-
CRP by 13-17%. Ridker et al. (2005) found that individuals with low hs-CRP 
concentrations following statin therapy had better clinical outcomes compared to those 
with higher hs-CRP concentrations. They found that event-free survival was significantly 
improved in acute coronary syndrome patients that reduced hs-CRP levels to less than 2 
mg/L following statin therapy. This effect was seen at all levels of LDL. Ridker et al. 
(2005) stated, "Our data also provide support for ongoing efforts to find agents capable of 
lowering CRP as a potential method of reducing vascular risk". Controversy, 
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unfortunately, exists as to whether statin therapy is appropriate in primary prevention in 
individuals with high hs-CRP, but normal lipid levels. Therefore, lifestyle therapy may 
be more appropriate in these individuals. Physical activity, for example, may actually 
reduce hs-CRP to a greater extent than pharmacological therapies. 
E. Hs-CRP and Physical Activity 
It is well known that regular physical activity reduces the risk of cardiovascular 
disease (Erikssen et al., 1998), and recent studies have found an association between 
physical activity and hs-CRP. Regular exercise appears to diminish the acute phase 
reaction, which suggests suppression of the inflammatory response (Mattusch, Cufaux, 
Heine, Mertens, and Rost, 2000). Intervention studies have shown reductions in hs-CRP 
in exercise groups compared to controls. Geffken et al. (2001) found an inverse 
relationship between hs-CRP and regular physical activity among healthy elderly 65 
years) participants (n = 5,201 participants, 2,961 females, 2,239 males). Mattusch et al. 
(2000) found that nine months of endurance training reduced hs-CRP levels by 31% 
when compared to non-training controls. Following six months of supervised exercise 
training Smith, Dykes, Douglas, Krishnaswamy, and Berk (1999) observed a 35% 
reduction in hs-CRP in individuals (n = 43) at high risk of ischemic heart disease. 
Although these studies supply evidence that hs-CRP levels are reduced by regular 
physical activity, they lack either generalizability, fail to adjust for body weight and other 
confounding variables, or fail to account for drop outs. For example, Mattusch et al. 
(2000) failed to control for known confounding variables such as the presence of 
cardiovascular disease, race, smoking, age, diabetes, hypertension, and body mass index, 
which improved the quality of the study. 
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Mattusch et al. (2000) measured hs-CRP before and after nine months of 
marathon training in fourteen participants. During the training, distance run increased 
significantly as did the subjects aerobic capacity. Following training hs-CRP levels were 
reduced (1.19 mg/L to 0.82 mg/L). This was an unexpected result since intense exercise 
has been associated with inflammation of muscles and tendons. Mattusch et al. (2000) 
concluded that a decrease in hs-CRP following intense endurance training suggests that 
intense regular exercise has a systemic anti-inflammatory effect. 
Mattusch et al. (2000) provided preliminary intervention data showing reduced 
hs-CRP levels following training. Results of this study are limited to males training for a 
marathon, therefore we can not generalize the results. Data from several participants was 
thrown out and not used in the statistical analyses, which could have created bias. 
Mattusch et al. (2000) failed to control for diet. Several dietary factors influence hs-CRP 
levels. Omega-3 fatty acid consumption for example, may reduce hs-CRP level 
(McCarty, 1999). Mattusch et al. (2000) also failed to adjust for body weight. 
Reductions in body weight can reduce hs-CRP (Pearson et al., 2003). Hence, we don't 
know if the reduction in hs-CRP were due to exercise independently. 
In many individuals inflammation is a result of obesity, particularly central 
obesity (Ridker, 2003). Many researchers have found strong positive associations 
between hs-CRP and waist girth, body fat mass, and visceral adiposity. LaMonte et al. 
(2002) found significant correlation between hs-CRP and waist girth, BMI, insulin, 
fitness level, and triglycerides. They examined the relationship between plasma hs-CRP 
and fitness level in 45 Native American (NA), 44 African American (AA), and 46 
Caucasian (CA) women. Hs- CRP was measured following a 12-hour fast and 24-hour 
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abstinence from exercise and smoking. Duration of a maximal treadmill test was used to 
quantify fitness. A general linear model was used to analyze differences in hs-CRP 
concentrations across categories of race, fitness, and BMI. Treadmill exercise times were 
adjusted for age with linear regression and used to quantify fitness level. LaMonte et al. 
(2002) found hs-CRP was decreased in those with higher fitness levels and was increased 
in those with higher BMI and waist girth. They also found that hs-CRP levels varied by 
race. Lower hs-CRP levels were observed across tertiles of race-specific treadmill times 
in CA and NA, but not in AA after adjusting for BMI, smoking, diabetes, and estrogen 
status. The mechanisms for racial differences were unknown. 
Rawson et al. (2003) found that BMI, not physical activity was associated with a 
reduction in hs-CRP. They measured hs-CRP five times over one year and examined the 
effects of BMI and both current and previous year physical activity in healthy men and 
women (n = 109). Current physical activity was measured using a telephone interview 
with a standardized interview script and a Baecke questionnaire was used to assess the 
previous year's physical activity. Over the course of the study physical activity 
increased, while BMI and hs-CRP remained unchanged. Only BMI was significantly 
related to hs-CRP when current physical activity, BMI, age, gender, and smoking were 
included in the statistical model. Current physical activity was similar when grouped by 
BMI (obese, overweight, normal) and was unrelated to hs-CRP. It may be that BMI was 
measured with greater reliability than physical activity, hence the association between 
BMI and hs-CRP was stronger than the association between physical activity and hs-
CRP. Rawson et al. (2003) also found that as BMI increased, levels of hs-CRP increased. 
The lack of an association between physical activity and hs-CRP was surprising, as other 
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studies have found reductions in hs-CRP with increased physical activity. Discrepancies 
between this study and others could have resulted from cohort differences, subject 
screening and study design. For instance, the participants in Geffken et al. were older (79 
years vs. 49 years). Hs-CRP is affected by age (Pearson et al., 2003). The study 
conducted by Smith et al. (1999) assessed hs-CRP in participants at risk for 
cardiovascular disease taking lipid-lowering medications. Some lipid lowing medications 
are known to reduce hs-CRP levels (Pearson et al., 2003). The cohort in the Rawsen et 
al. study was largely sedentary throughout the study while the participants in the Smith et 
al. and Geffken et al. studies were more physically active. In order to reduce hs-CRP, 
higher levels of physical activity may be needed when BMI remains stable. Respondent 
bias could also have lead to discrepancies between this study and others. It is well known 
that retrospective judgments can be biased. A number of factors influence retrospective 
data, such as the length of time since the event being recalled and specificity versus 
generality of information needed. Recalling physical activity over the past year may have 
been difficult, resulting in greater respondent error. If the survey used asked the 
participants specific events, the chance of inaccurate recall would have increased. 
Interviewer technique could also have introduced bias. 
Physical activity has also been associated with reduced insulin resistance and 
reduced visceral obesity (Tracey, 2001). According to an editorial written by Tracey 
(2001) the Insulin Resistance and Atherosclerosis Study (IRSA) reported a strong 
association between insulin resistance and visceral adiposity. According to Tracey the 
study concluded that central obesity was the critical correlate of hs-CRP. Other 
researchers have found cardiorespiratory fitness levels to be inversely associated with hs- 
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CRP independent of body mass index (BMI). Wannamethee et al. (2002) examined the 
association between regular leisure-time activity and hemostatic and inflammatory 
variables. They found that physical activity was significantly and inversely associated 
with several hemostatic and inflammatory variables, including hs-CRP. This association 
persisted after adjustment for age, BMI, smoking, alcohol, and preexisting CVD. 
Church et al. (2002) also found an association between cardiorespiratory fitness 
and hs-CRP independent of BMI. Cardiorespiratory fitness was assessed by a maximal 
treadmill test using a modified Balke protocol. They adjusted for weight and within 
weight categories. Participants (n = 722) were part of the Aerobic Center Longitudinal 
Study (ACLS), an epidemiological study of patients who received a preventive medical 
examination at the Cooper Clinic in Dallas, Texas. Church et al. calculated median and 
adjusted geometric mean hs-CRP levels, odds ratios of elevated hs-CRP across five levels 
of cardiorespiratory fitness, and percentages of individuals with hs-CRP 2 mg/L. They 
adjusted for age, BMI, smoking habit, vitamin use, statin medication, use of aspirin, and 
known inflammatory disease, CVD, and diabetes. An inverse association was found 
across fitness levels. Hs-CRP was highest in the lowest fitness quintile and lowest in the 
most fit quintile. Results were similar when the hs-CRP-fitness relationship was 
examined within categories of body fatness (normal weight, overweight, and obese). 
Church et al. (2002) had a number of strengths in their study. They used 
metabolic equivalents (METs) as an objective measure of cardiorespiratory fitness, they 
had a large sample size, a thorough medical history, and in depth information on 
smoking, medication and vitamin use. Another important strength was the examination 
of fitness and hs-CRP with different levels of body composition and fat distribution. 
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Although this study had numerous strengths it also had limitations. Diet was not 
evaluated. Diet may influence hs-CRP and those that exercise regularly often have 
healthier diets than non-exercisers. The population studied was predominantly white, 
middle-to-upper class, which limits the ability to generalize the results. Although this 
homogenous group reduces external validity it improved internal validity by reducing the 
likelihood of confounding variables. 
F. Possible Mechanisms for Reduced Hs-CRP Following Training 
Several theories exist as to how regular exercise reduces hs-CRP and the 
inflammatory process. Mattusch et al. (2000) suggested that hs-CRP levels were 
reduced, at least in part, due to enhanced antioxidative defense mechanisms seen after 
regular exercise training. It has been reported that well trained athletes have increased 
activity in muscular and erythrocytic antioxidative enzymes. Animal studies have also 
shown improved antioxidant defense mechanisms after exercise training. It may be that 
enhanced antioxidative protection reduces the production of IL-6 and other cytokines in 
the exercising muscle (Mattusch, 2000). 
Church et al. (2002) also proposed interleukins as a potential pathway. Evidence 
suggests that TNF-a and IL-6 are involved in hs-CRP production. TNF-a and IL-6 are 
released from adipose tissue, particularly visceral sites. Their release is augmented by 
the down-regulation of sympathetic stimulation via regular physical activity. This may 
lead to a reduction in hs-CRP. TNF-a stimulates the production of IL-6 and IL-6 
stimulates the production of hs-CRP. Unlike a single bout of exercise which may 
increase plasma levels of IL-6, IL-1B, and other associated inflammatory markers, 
repeated exercise training appears to lower basal plasma interleukin concentrations. 
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TNF-a also appears to be reduced following regular exercise training. Reduction in TNF-
a and IL-6 have been found independently of weight loss, hence, TNF-a and IL-6 may be 
responsible for reduced hs-CRP in fit individuals (Church et al., 2002). 
Smith et al. (1999) found that exercise reduced TNF-a. These researchers 
examined the possibility that long-term exercise could favorably alter the production of 
cytokines with atherogenic and atheroprotective properties. Cytokines with atherogenic 
properties include IL-1, TNF-a, and IFN-y. Cytokines with atheroprotective properties 
include IL-4, IL-10, and transforming growth factor beta (TGF-B). Smith et al. (1999) 
measured the effects of exercise on the production of these cytokines by blood 
mononuclear cells. They also examined the effects of exercise on serum levels of hs-
CRP. Following six months of moderate intensity training, blood mononuclear cell 
production of cytokines was attenuated, while the production of cytokines with 
atheroprotective properties was increased. These changes were proportionate to the time 
participants spent performing repetitive lower-body exercises, which would suggest a 
dose-response relationship. A reduction in hs-CRP accompanied the changes in immune 
cell function. This could indicate a systemic reflection of decreased IL-la and TNF-a 
production. These alterations were independent of aspirin or other medication use, 
dieting, weight loss, or smoking cessation. Smith et al. (1999) also found a significant 
attenuating effect on IFN-y and TNF-a following training. Because both of these 
cytokines have been identified in early and advanced atherosclerotic lesions this is a 
favorable sign in persons at risk of developing cardiovascular disease. Endothelial cells, 
monocytes, macrophages, and smooth muscle cells are activated by these cytokines, 
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hence they contribute to leukocyte recruitment, endothelial cell procoagulant activity, 
LDL oxidation, and foam cell formation in atherosclerotic lesions. 
Few studies have examined the effects of exercise on hs-CRP therefore the 
mechanisms remain largely unknown at this time. Further studies are clearly warranted. 
G. Conclusions 
There is increasing evidence that atherosclerosis is a dynamic and progressive 
disease resulting from the combination of inflammation and endothelial dysfunction. 
Advances in basic and experimental science have established that inflammation is 
involved in mediating all stages of this disease from initiation through progression and, 
ultimately, to atherosclerotic plaque complications (Pearson et al., 2003; Libby, Ridker, 
& Maseri, 2002). These new findings not only provide a link between risk factors and 
the mechanisms of atherogenesis, but the connection between inflammation and 
atherosclerosis also provides predictive and prognostic information (Libby, Ridker, & 
Maseri, 2002). Several markers of the inflammatory cascade have been examined as 
potential tools in the prediction of cardiovascular events. Hs-CRP is one of those 
markers and has generated much interest (Szmitko et al., 2003). Emerging evidence 
suggests that hs-CRP is one of the strongest independent predictors of cardiovascular 
events and may play a functional role in the atherosclerotic disease process (Szmitko et 
al., 2003; Yeh & Willerson, 2003). It appears to be even better than low-density 
lipoprotein (LDL) cholesterol at predicting cardiovascular events. This new information 
is profound and is beginning to change the way we screen and manage patients (Yeh & 
Willerson, 2003). 
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It is well known that regular physical activity is associated with lower risk of 
coronary heart disease, stroke, and cardiovascular mortality. Although the mechanisms 
are unclear, evidence suggests that physical activity modifies the inflammatory process. 
Recent studies have demonstrated an inverse relationship between inflammatory markers 
such as hs-CRP and physical activity. At this time only a handful of studies have 
examined the effects of exercise on hs-CRP and results are conflicting. More research is 
clearly needed to assess the relationship between hs-CRP and physical activity. 
Questions remain regarding: (1) the type and intensity of exercise needed to reduce hs-
CRP, (2) whether the association seen between physical activity and lowered hs-CRP is 
mediated by reduced body fat, and (3) whether fitness level modifies hs-CRP in those 





The purpose of this study was to examine the relationship between hs-CRP, 
metabolic syndrome and physical activity. Understanding this relationship will provide 
insight into the potential of physical activity as a therapeutic option to reduce 
cardiovascular disease risk. This study relied on a cross-sectional, retrospective analysis 
of an archival database. Study participants were obtained from a pool of 1,072 men and 
women patients at the Center of Health Promotion (CHP) at Loma Linda University. Of 
the 1,072 pool, 173 individuals met the inclusion criteria and were the subjects of the 
study. Any missing data variables were imputed using the maximum likelihood method 
(EM) in SYSTAT version 10; SPSS©2000. Simple regression/correlation analysis was 
used to evaluate the relationships between log (CRP) and each of the relevant variables: 
VO2max (ml-kg-l•min-1), metabolic syndrome, and the physical activity status. The 
following relationships were explored: (1) hs-CRP and metabolic syndrome 
characteristics, (2) hs-CRP and VO2max, (3) VO2max and metabolic syndrome 
characteristics, and (4) VO2max and physical activity status. Pearson Chi-square analysis 
was used to determine if a threshold level of physical activity was associated with hs-
CRP changes. 
B. Subjects 
Study participants were selected from a pool of 1,072 men and women that 
underwent a medical exam at the Center for Health Promotion (CHP). The CHP is a 
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preventive health clinic that provides preventive medicine services to Southern California 
communities. Participants were, at the time of measurement, residents of Southern 
California's Inland Empire residing in San Bemadino and Riverside counties. 
Participants were included in this study if they: (1) underwent a medical exam at the CHP 
at Loma Linda University, which included blood pressure screening and blood analysis• 
(hs-CRP, lipid profile and fasting blood glucose), (3) completed a Comprehensive 
Personal Wellness Profile (PWP) questionnaire regarding their medical history and 
lifestyle health practices (Wellsource Inc., Clachamus, OR), (4) attained 85% of 
estimated maximal heart rate on a Bruce protocol treadmill stress test at the CHP, and 5) 
were able to give informed consent. Failure to meet all of these criteria resulted in 
exclusion from the study. A total of 173 patients fulfilled the criteria and were included 
as the subjects of this study. 
C. Measurement Variables 
Cardiorespiratory fitness level was assessed via maximal oxygen uptake 
(V02max, expressed in ml.kg-1-min-1) estimated from a Bruce protocol treadmill stress 
test. The PWP questionnaire was used to collect information regarding the participant's 
medical history and lifestyle behaviors such as: smoking habits, alcohol intake patterns, 
eating habits, stress and coping patterns, social health, and physical activity status. 
Several questions were asked regarding the participant's physical activity status. 
Participants were asked about their current physical activity status under the headings of: 
(1) no regular exercise program, (2) occasionally walk for pleasure, (3) regular exercise 
in work or recreation requiring modest physical activity such as golf, yard work, 
calisthenics, up to one hour per week, (4) regular exercise in work or recreation requiring 
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modest physical activity such as golf, yard work, calisthenics, more than one hour per 
week, or (5) more active physical exercise (brisk walking, jogging, swimming). If the 
participant answered yes to the last question they indicated how much time was spent 
engaging in that activity each week. 
Quest diagnostics performed the blood chemistry analyses. They annually 
perform over 100 million personal health tests, over 250 million diagnostic laboratory 
tests, and more than 6.5 million gene-based tests. They are CLIA Certified and their 
main laboratories are College of American Pathologists accredited. Plasma CRP 
concentrations were measured with the Dade Bering BN II high-sensitivity immunoassay 
(Dade Behring, Inc. IL). Fasting glucose were performed on the Olympus AU5400 
Analyzer (Olympus America Inc., NY). Total cholesterol and triglyceride analyses were 
performed on the Olympus AU5400 Analyzer, while HDL-cholesterol was performed on 
a Roche Analyzer (Roche Molecular Systems Inc., CA). 
Participants had their resting blood pressure measured by auscultation. Standard 
procedures outlined by the American Medical Association were followed (Reeves, 1995) 
Weight was measured on a standardardized physician's balance beam scale and 
stadiometer. BMI (weight (kg)/height (m)2) was also calculated for each. 
Although the definition of Metabolic Syndrome has not been agreed upon 
internationally, a working definition continues to be used (Ford, Giles, and Mokdad, 
2004; Kahn, Buse, Ferrannini, and Stern, 2005). Our definition utilizes criteria set forth 
by both the WHO and the U.S. National Cholesterol Education Program Adult Treatment 
Panel III (ATP III) guidelines (The Expert Panel, 2001; Kahn, Buse, Ferrannini, and 
Stern, 2005). Participants had to meet at least three of the following variables in order to 
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be labeled as having metabolic syndrome: (1) blood pressure 130/85 mm Hg, (2) HDL-
C <40 mg/di for males, <50 mg/di for females, (3) fasting blood glucose 110mg/d1, (4) 
elevated TG 1.50 mg/di, and (5) BMI ?_30kg/m2. Due to the retrospective design of this 
study and the lack of waist circumference measurements we chose to use BMI 
WOkg/m2) as our measure of obesity rather than waist circumference. The WHO 
definition utilizes 30kg/m2 as criteria for obesity.12 
D. Data Analysis 
A total of 173 patients fulfilled the inclusion criteria and were included as the 
subjects of this study. Any missing data variables were imputed using the maximum 
likelihood method (EM) in SYSTAT version 10; SPSS©2000. Because the percent body 
fat variable required over 100 imputations to fill in all of the missing data it was not used 
in any analyses. The distribution of hs-CRP, the dependent variable of greatest interest, 
was positively skewed. Therefore, a log transformation was applied to hs-CRP values for 
all analyses. Simple regression/correlation analysis was used to evaluate the relationships 
between log (CRP) and each of the relevant variables: VO2max (ml•kg-1•min-1), 
metabolic syndrome, and the physical activity status. The following relationships were 
explored: (1) hs-CRP and metabolic syndrome characteristics, (2) hs-CRP and VO2max, 
(3) VO2max and metabolic syndrome characteristics, and (4) VO2max and physical 
activity status. Pearson Chi-square analysis was used to determine if a threshold level of 
physical activity was associated with hs-CRP changes. 
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E. Power Analysis 
When designing the study a medium effect size was assumed. Power analysis 
was conducted using the statistical software GPO WER (Faul & Erdfelder, 1992). 
Multiple regression analysis was the statistical test used to determine power along with a 
medium effect size (0.15), an alpha of 0.05, and power of 0.80. The total sample size 
needed according to the GPO WER analysis was 131 participants. 
F. Limitations 
The proposed study has several limitations: (1) reporting bias, (2) health habits of 
regular exercisers, (3) failure to control physical activity prior to blood draw, and (4) lack 
of detailed medication history prior to blood draw. Participants may have embellished 
when filling out the physical activity portion of the PWP. This respondent bias could 
threaten the studies validity. 
People that exercise regularly may also engage in other positive health behaviors, 
thereby reducing hs-CRP levels. Regular exercisers, for example, may have healthier 
diets than those that do not exercise regularly (Church 2002). This could influence their 
hs-CRP levels. In addition to healthier eating habits, regular exercisers may have reduced 
stress, anxiety, and depression (Petruzzello, Landers, Hatfield, Kubitz, and Salazar, 1991; 
Plante, Unger, Hutchinson, and Faigenbaum, 1990) compared to non-exercisers. Mental 
state may influence markers of inflammation (Appels, Bar, Bar, Bruggeman, and 
DeBaets, 2000). According to Black (2003), an acute phase reaction may be induced by 
stress alone. IL-6 is the central mediator of the acute phase reaction and it facilitates the 
production of several acute phase proteins, including hs-CRP. Hence, if a person 
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exercises regularly, thereby reducing stress, he or she may in turn decrease hs-CRP levels 
independently of exercise. 
Intense exercise leads to increased inflammation, hence hs-CRP levels will be 
elevated (Mattusch et al. 2000). The participants were not instructed to refrain from 
exercising prior to the blood draw. If a participant engaged in some form of exercise 
prior to the blood draw hs-CRP levels could have been transiently elevated, thereby 
affecting the study's validity. 
Research is finding that certain medication may also influence hs-CRP values. 
Medications such as statins, fibrates, and niacin appear to reduce hs-CRP, while hormone 
replacement therapy appears to elevate hs-CRP levels (Pearson et al., 2003). The PWP 
does not provide detailed medication history. Lack of this knowledge could affect 
validity. 
G. Research Ethics 
Risk to participants is minimal. In order to protect participant confidentiality 
individual data will be coded and sorted by identification numbers. The list matching 
names and identification numbers will be stored separately from the data and both will be 
kept in locked filing cabinets. The identity of the participants will be known to the 
principal investigator, co-investigators, and statistical consultant. Signed consent forms 
will be kept in a locked storage facility at the CHP at Loma Linda University. Access 
will be restricted to the principal investigator, co-investigator, and designated 
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The Relationship Between High Sensitivity C-Reactive Protein, Metabolic 
Syndrome, and Exercise 
Background—Metabolic syndrome (MetS) is characterized by three or more of 
the following criteria: low high density lipoprotein (HDL), hypertriglyceridemia, 
hypertension, obesity, and abnormal glucose. High sensitivity C-reactive protein (hs-
CRP) increases linearly with the number of MetS criteria. Both MetS and hs-CRP are 
associated with increased risk of cardiovascular disease (CVD) and diabetes. 
Cardiorespiratory fitness (CRF) is negatively associated with both the MetS and hs-CRP. 
CRF is associated with reduced risk of diabetes and CVD. 
Methods and Results—We examined the relationship between hs-CRP, MetS, 
and CRF in 173 men and women. CRF was assessed using a Bruce protocol treadmill 
test and expressed as maximal oxygen uptake (VO2max). Physical activity status was 
also assessed via self report. Plasma hs-CRP levels were determined using standardized 
immunoassay. Hs-CRP increased linearly with the number of MetS characteristics (p = 
0.00022). An inverse association was found between hs-CRP and VO2max (p = 0.00008) 
and between VO2max and the number of MetS criteria (p = 0.00004). VO2max was 
positively associated with physical activity pattern (p = 0.00000). Subjects engaging in 
2-3 hours of exercise per week had hs-CRP levels < 2.5 mg/L (p = 0.01817). 
Conclusion—Higher hs-CRP levels are associated with lowered CRF and higher 
number of MetS criteria. These associations are suggested mechanisms by which CRF 
reduces the risk of CVD and diabetes. 
Key Words: C-reactive protein II Exercise ll Metabolic Syndrome ll Atherosclerosisll 
Inflammation 
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The leading cause of death in the U.S. is cardiovascular disease (CVD).1 Today, 
it is well known that insulin resistance plays an integral role in CVD etiology. 2-3 Certain 
CVD risk factors appear to be exacerbated by insulin resistance. According to the Adult 
Treatment Panel-III (ATP-III) Guidelines4 metabolic syndrome is characterized by three 
or more CVD risk factors which include the following: abdominal obesity, low high 
density lipoprotein (HDL) cholesterol, elevated serum triglycerides (TG), elevated resting 
blood pressure, and impaired fasting glucose.1'5 The prevalence of metabolic syndrome 
in adults aged 	years has increased from 41 million in 1990 to approximately 55 
million in 2000.6  Individuals with metabolic syndrome are at increased risk for both 
diabetes and cardiovascular disease.6 Coronary artery disease, stroke, and myocardial 
infarction appear to be increased nearly threefold. 7 Hence, the ATP-III report stresses 
the significance of preventive therapies in these individuals. 
It is well known that regular physical activity reduces the risk of chronic diseases 
such as diabetes and cardiovascular disease. 8 Physical activity is also considered an 
important determinant of metabolic syndrome.6 All levels of metabolic syndrome, 
diabetes, and cardiovascular disease are thought to involve inflammation. Physical 
activity may reduce risk, at least in part, by modifying the inflammatory process. Recent 
studies have demonstrated an inverse relationship between inflammatory markers, such 
as high sensitivity C-reactive protein (hs-CRP), and physical activity.9'10 Elevated hs-
CRP appears to be an independent predictor of both cardiovascular disease and diabetes. 
Recent evidence also suggests that hs-CRP is positively associated with all metabolic 
syndrome characteristics.5 Ridker et a1,5 stated that hs-CRP adds prognostic value to all 
levels of metabolic syndrome. Based on these findings we sought to evaluate the 
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relationship between hs-CRP, metabolic syndrome, and cardiorespiratory fitness (CRF), 
expressed as maximal oxygen uptake (ml•kg-l.min-1). 
Methods 
Study sample 
Study participants were selected from a pool of 1,072 men and women from the Center of 
Health Promotion (CHP) at Loma Linda University. Participants were included in this 
study if they: (1) underwent a preventive medicine health exam at the CHP, which 
included blood pressure screening and blood analysis (hs-CRP, lipid profile, and fasting 
blood glucose), (3) completed Comprehensive Personal Wellness Profile (PWP) 
questionnaire regarding their medical history and lifestyle health practices (Wellsource 
Inc., Clachamus, OR), (4) reached 85% of age predicted maximal heart rate on a Bruce 
protocol treadmill stress test, and 5) were able to give informed consent. 173 subjects 
met the criteria and were included in the study. 
Clinical Measurements 
Cardiorespiratory fitness level was assessed via maximal oxygen uptake (V02max, 
expressed in ml-kg-1•min-1) estimated from a Bruce protocol treadmill stress test. The 
PWP questionnaire was used to collect information regarding the participant's medical 
history, and lifestyle behaviors such as: smoking habits, alcohol intake patterns, eating 
habits, stress and coping patterns, social health, and physical activity status. Several 
questions were asked regarding the participant's physical activity status. Participants 
were asked about their current physical activity status under the headings of: (1) no 
regular exercise program, (2) occasionally walk for pleasure, (3) regular exercise in work 
or recreation requiring modest physical activity such as golf, yard work, calisthenics, up 
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to one hour per week, (4) regular exercise in work or recreation requiring modest 
physical activity such as golf, yard work, calisthenics, more than one hour per week, or 
(5) more active physical exercise (brisk walking, jogging, swimming). If the participant 
answered yes to the last question they indicated how much time was spent engaging in 
that activity each week. 
Quest diagnostics performed the blood chemistry analyses. Plasma hs-CRP 
concentrations were measured with the Dade Bering BN II high-sensitivity immunoassay 
(Dade Behring, Inc. IL). Fasting glucose was performed on the Olympus AU5400 
Analyzer (Olympus America Inc., NY). Total cholesterol and triglyceride analyses were 
performed on the Olympus AU5400 Analyzer, while HDL-cholesterol was performed on 
a Roche Analyzer (Roche Molecular Systems Inc., CA). 
Participants had their resting blood pressure measured by auscultation. Standard 
procedures outlined by the American Medical Association were followed.11 Weight was 
measured on a standardized physician's balance beam scale and stadiometer. BMI 
(weight (kg)/height (m)2) was also calculated for each participant. 
Definitions 
Although the definition of Metabolic Syndrome has not been agreed upon internationally, 
a working definition continues to be used.6'12 Our definition utilizes criteria set forth by 
both the WHO (Table 1) 12  and the U.S. National Cholesterol Education Program Adult 
Treatment Panel III (ATP III) guidelines (Table 2). 4, 12,13 Participants had to meet at least 
three of the following variables in order to be labeled as having metabolic syndrome: (1) 
blood pressure 1.30/85 mm Hg, (2) HDL-C <40 mg/di for males, <50 mg/di for females, 
(3) fasting blood glucose 110mg/d1, (4) elevated TG 150 mg/di, and (5) BMI 
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..30kg/m2. Due to the retrospective design of this study and the lack of waist 
circumference measurements we chose to use BMI WOkg/m2) as our measure of obesity 
rather than waist circumference. The WHO definition utilizes .30kg/m2 as criteria for 
obesity.12 
Statistical Methods 
Any missing data variables were imputed using the maximum likelihood method (EM) in 
SYSTAT version 10; SPSS©2000. Because the percent body fat variable required over 
100 imputations to fill in all of the missing data it was not used in any analyses. The 
distribution of hs-CRP, the dependent variable of greatest interest, was positively skewed. 
Therefore, a log transformation was applied to hs-CRP values for all analyses. Simple 
regression/correlation analysis was used to evaluate the relationships between log (CRP) 
and each of the relevant variables: VO2max (ml•kg-l•min-1), metabolic syndrome, and the 
physical activity status. The following relationships were explored: (1) hs-CRP and 
metabolic syndrome characteristics, (2) hs-CRP and VO2max, (3) VO2max and metabolic 
syndrome characteristics, and (4) VO2max and physical activity status. Pearson Chi-
square analysis was used to determine if a threshold level of physical activity was 
associated with hs-CRP changes. 
Results 
The mean age of the 173 subjects evaluated in the study was 49.51 (9.8) years. Clinical 
characteristics of the study participant are shown in Table 3. 8.7% of our subjects met 
the metabolic syndrome criteria. As shown in Figure 1, hs-CRP increased linearly with 
the number of metabolic syndrome criteria (p = 0.00022). Figure 2 describes the 
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relationship between hs-CRP and VO2max. An inverse association was found between 
hs-CRP and VO2max (p = 0.00008). An inverse relationship was also found between 
VO2max and the number of metabolic syndrome criteria (p = 0.00004). VO2max was 
positively related with physical activity status (p = 0.00000). Hence, fitness level was 
increased, at least in part, by the amount of physical activity the participants engaged in. 
The Surgeon General advises individuals of all ages to engage in a minimum of 
30 minutes of moderate physical activity on most, if not all, days of the week to improve 
health and reduce risk of chronic disease.14 The American College of Sports Medicine 
(ACSM) recommends a minimum of 150 minutes per week of moderate-intensity 
exercise for health benefits. 15  Our findings supports the Surgeon General's physical 
activity recommendations and recommendations set by the ACSM.14'15 Subjects in our 
study engaging in 2-3 hours of exercise per week had hs-CRP levels < 2.5 mg/L (p = 
0.01817), which is considered low to moderate risk. 
Discussion 
An apparent common theme that appears to connect most of the metabolic syndrome risk 
factors is inflammation (Figure 3).192122 Inflammation plays a role in elevated blood 
pressure, dyslipidemia, impaired glucose tolerance, and obesity.19,21,22 The present study, 
in agreement with others,5'7 found a positive relationship between the acute phase protein 
(APP), hs-CRP, and metabolic syndrome characteristics. We found inverse associations 
between: (1) hs-CRP and CRF level and (2) CRF level and metabolic syndrome severity. 
It may be postulated that CRF reduces each of the risk factors seen in the metabolic 
syndrome via a reduction in the inflammatory process. 
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Several studies have found an inverse relationship between inflammatory markers 
and physical activity.16-18 The proinflamatory cytokines IL-6 and tumor necrosis factor-a 
(TNF-a) are involved in hs-CRP production. Regular exercise training appears to lower 
basal plasma interleukin concentrations, such as IL-6, and TNF-a, 16-18 which in turn 
downregulates hs-CRP production. According to Ghanim et a1,19 as transcriptional 
activity of TNF-a and IL-6 is increased, intranuclear binding of the proinflammatory 
transcription factor nuclear factor-kappa B (NF-KB) is increased. It is suggested that 
exercise down modulates activation of NF-KB,7  thereby reducing TNF-a, IL-6, and CRP. 
This reduction in inflammation may in turn reduce risk factors seen in the metabolic 
syndrome. 
It is well known that exercise improves blood pressure.2° This improvement is 
likely due to several mechanisms, including reduced cytokines and APP. Hypertension 
appears to stimulate production of cytokines such as IL-6 and other inflammatory 
mediators from the endothelium. Elevated cytokines along with APPs may impair 
endothelial dependent vasodilation.21'22  In addition to impaired vasodilation, chronic 
cytokinemia may contribute to insulin resistance, which leads to hyperinsulinemia. 
Hyperinsulinemia in turn stimulates the autonomic centers of the brain, which leads to an 
increase in catecholamine secretion, hence, the strong correlation between hypertension 
and insulin resistance syndrome. 21  Catecholamines, such as norepinephrine (NE), may 
induce an acute phase reaction (APR). 21  Thus, atherosclerotic plaque buildup can ensue 
due to the endothelial damage resulting from these events. 
Numerous studies have found exercise training reduces proinflammatory 
cytokines, such as IL-6, and APPs such as CRP.17-19 These reductions may in turn 
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improve insulin resistance, hyperinsulinemia, and reduce NE secretion, thereby reducing 
high blood pressure. Exercise may also reduce blood pressure via improved vasodilation. 
Studies have found exercise enhances the action of vasodilators, such as nitric oxide 
(NO).24 This may be due to the reduction in cytokines and APPs. 
Another important metabolic syndrome characteristic, impaired glucose tolerance, 
is also improved with regular exercise. This improvement is likely due to several 
mechanisms, including reduced inflammation. Inflammation may activate NF-KB 
signaling pathways via up-regulation of INF-a and IL-6, which stimulate hepatic CRP 
production.22  TNF-a may then contribute to insulin resistance by increasing oxidation of 
free fatty acid (FFA), stimulating additional cytokines (i.e. IL-6), inhibiting GLUT-4 
transporters, harming endothelial function, and/or impairing glucose-stimulated release of 
insulin by B-cells.22 Hyperglycemia induces IL-6 from macrophages and the 
endothelium. 21 IL-6 appears to reduce insulin signaling at the insulin receptor substrate-
1 level. 19  Hyperglycemia also decreases insulin sensitivity, which appears to enhance 
CRP production.21 The ensuing hyperinsulinemia stimulates IL-6 and TNF-a. 
Endothelial nitric oxide synthase-mediated vasodilaiton becomes impaired via the 
inflammatory cytokines and associated abnormal FFA oxidation. Reducing inflammation 
may be an important mechanism by which exercise improves glycemic control. Regular 
exercise has been found to increase the expression of GLUT 4 transporters25'26'27 and the 
expression of insulin receptor substrate-1 (IRS-1).27 These alterations may be due in part 
to a reductions in TNF-a and IL-6, respectively. Exercise has been found to improve 
glucose tolerance and both peripheral and hepatic insulin sensitivity. 25,27,28 These 
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improvements will likely lead to reduced cytokine and APP release, further improving 
glycemic control. 
Dyslipidemia, another risk factor seen in metabolic syndrome is also improved by 
exercise. Exercise, particularly aerobic exercise, appears to increase HDL and reduces 
TG.  25,28 
Sympathetically induced cytokines depress lipoprotein lipase (LPL). 21 In 
mice, TNF-a and IL-6 have been found to reduce LPL activity. 21 Exercise appears to 
enhance activity of several enzymes involved in lipid metabolism, including LPL. 28  
Hence, exercise may enhance LPL activity via cytokine reduction thereby improving 
dyslipidemia. 
The last metabolic syndrome characteristic is obesity. It is well known that 
exercise has a positive effect on this risk factor as measured by BMI or body fat 
percent.21 It may be that exercise reduces inflammation via a reduction in 
adiposity.16,29,30,31 Exercise appears to reduce visceral adipose tissue.32 This may be an 
important mechanism by which exercise reduces inflammation. It is now recognized that 
adipose tissue functions in part as an immune organ.33 It secretes many 
immunomodulatory factors and sends inflammatory signals known to cause insulin 
resistance.32 Ghanim et all9 found increased intranuclear NF-KB binding and increased 
concentrations of TNF-a and IL-6 in obese subjects. This proinflammatory state may 
contribute to insulin resistance in obese individuals as well as those with the metabolic 
syndrome. 
In adipose tissue, TNF-a reduces the expression of the insulin receptor and causes 
a reduction in tyrosine phosphorylation of the insulin receptor thereby interfering with 
insulin action.19'33 Although the intracellular pathways activated by TNF-a remain to be 
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established they are thought to involve NF-KB. 33 Once activated, TNF- a receptors 
activate inhibitor kappa B kinase (IKK) complex, which appears to be a mediator of 
insulin resistance. 33 The key catalytic subunit of the IKK complex, IKK2, 
phosphorylates inhibitor kappa B. 33 This leads to NF-KB translocation into the nucleus, 
which activates inflammatory target genes. 33 IKK also inactivates the insulin receptor 
and IRS-1, which leads to decreased activation of phosphoinosito1-3 kinase, a second 
messenger involved in the metabolic effects of insulin. 33 IL-6 also affects insulin's 
metabolic effects via a reduction in insulin signaling at the insulin receptor substrate-1 
leve1.19 
As previously mentioned, exercise increases the expression of IRS-1.27 It may be 
that exercise enhances expression of IRS-1 via a reduction in TNF-a and IL-6. Enhanced 
expression of IRS-1 may reduce interference in insulin's action. It may be that exercise 
reduces proinflammatory cytokines and the inflammatory response via a reduction in 
body fat, particularly a reduction in visceral adiposity. In this context, the present study 
has a couple important limitations. Inflammatory markers, such as cytokines, were not 
measured and waist circumference was not measured. 
Conclusions 
Elevated inflammation and the presence of the metabolic syndrome significantly increase 
the risk of CVD, diabetes, and premature mortality.34 We postulate that exercise reduces 
the risk of these conditions by reducing inflammation. We found that hs-CRP and the 
metabolic syndrome severity were reduced in those with a higher cardiorespiratory 
fitness level. We also found that those engaging in 2-3 hours of physical activity per 
week had lower hs-CRP levels (< 2.5 mg/L). Further clarification is needed to show 
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whether exercise reduces risk factors, thereby reducing inflammation or whether exercise 
reduces inflammation, thereby reducing risk factors. Regardless of which comes first, it 
appears that exercise is an important means of reducing risk factors seen in those 
individuals with metabolic syndrome. Aggressive therapeutic interventions of these 
individuals are imperative. The ATP-III report strongly supports the use of exercise as 
first-line therapy for the management of the metabolic syndrome.4'5 It would appear that 
our research fmdings add support to this recommendation. 
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Table 1. ATP Ill Clinical Identification of the Metabolic Syndrome* 
Risk Factor 	 Defining Level 
Abdominal obesity, (waist circumference) 
Men 	 >102 cm (>40 in) 
Women >88 cm (>35 in) 
Triglycerides 	 >150 mg/dL 
HDL cholesterol 
Men 	 <40 mg/dL 
• Women <50 mg/dL 
Blood pressure 	 >130L85 mm Hg 
Fasting glucose 110 mg/dL  
*Derived from Kahn et al.12 
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Table 2. WHO Clinical Identification of the Metabolic Syndrome* 
Insulin Resistance: (1 of the following) 
1) Type 2 diabetes 
2) Impaired fasting glucose 
3) Impaired glucose tolerance 
Plus any 2 of the following: 
1) Elevated BP (?_140/90) or Antihypertensive medication 
2) Plasma TG 50mg/dI 
3) HDL <35 in men, <40 in women 
4) BMI >30 &/or waist:hip ratio >0.9 in men, >0.85 in women 
5) Urinary albumin >20mg/min, or Albumin:Creatinine ratio 30mg/g 
*Derived from Kahn et al.12 
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Table 3. Characteristics of Study Participants (Mean±SD) 
Overall 
(n = 173) 
Age, y 	 49.5 ± 9.8 
Weight, lbs 	 187.7 ± 44.9 
Height, in. 68.3 	4.0 
BMI, kg/m2 
	
28.14 ± 5.8 
Systolic BP, mm Hg 	 110.0 ± 12.7 
Diastolic BP, mm Hg 69.1 ± 8.6 
Fasting Glucose, mg/dL 
	
93.6 ± 16.4 
Triglycerides, mg/dL 129.5 ± 83.3 
Total-C, mg/dL 
	
192.5 ± 39.9 
HDL-C, mg/dL 53.4 ± 15.6 
LDL-C, mg/dL 
	
113.2 ± 36.5 
Metabolic Syndrome Criteria 	 0.91± 1.1 
CRP, mg/L 
	
2.0 ± 2.0 
VO2max, 	 45.0 ± 9.2 
BMI indicates body mass index; HDL-C, high-density lipoprotein 
choesterol; LDL-C , low density lipoprotein cholesterol; Total-C, total 
cholesterol; CRP, C-reactive protein; VO2max, maximal oxygen 
uptake. 
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Figure 1. Relationship Between Log CRP and Metabolic Syndrome 
Criteria. Distribution of log CRP levels among 173 
participants according to the presence of 0, 1, 2, or 3 
metabolic syndrome criteria. Box plots demonstrate 
median, 25th, and 75th  percentile values of log CRP. 
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Figure 3. A Model Describing the Relationship Between Inflammation and 
Metabolic Syndrome Characteristics. IL-6 = interleukin-6, TNF-a = tumor 
necrosis factor- a, CRP = c-reactive protein, BP = blood pressure, TG = triglyceride, 
IGT = impaired glucose tolerance, DM = diabetes mellitus, NO = nitric oxide, ET-1 = 
endothilin-1, ICAM = intracellular adhesion molecule, VCAM = vascular cell 
adhesion molecule, ATiR = angiotensin type-1 receptor, MCP-1 = monocyte 
chemoaftractant protein-1, NFKB = nuclear factor KB, Ang. II = angiotension type II, 
IRS-1 = insulin receptor substrate 1, LPL = lipoprotein lipase, SNS = sympathetic 
nervous system. 
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Figure 1. Distribution of log CRP levels among 173 participants according to the 
presence of 0, 1, 2, or 3 metabolic syndrome criteria. Box plots demonstrate median, 
25th, and 75th percentile values of log CRP. 
Figure 2. Inverse relationship between log CRP and VO2max. 
Figure 3. A model describing the relationship between inflammation and metabolic 
syndrome characteristics. IL-6 = interleukin-6, TNF-a = tumor necrosis factor-a, CRP = 
c-reactive protein, BP = blood pressure, TG = triglyceride, IGT = impaired glucose 
tolerance, DM = diabetes mellitus, NO = nitric oxide, ET-1 = endothilin-1, ICAM = 
intracellular adhesion molecule, VCAM = vascular cell adhesion molecule, ATI R = 
angiotensin type-1 receptor, MCP-1 = monocyte chemoattractant protein-1, NFKB = 
nuclear factor KB, Ang. II = angiotension type II, IRS-1 = insulin receptor substrate 1, 
LPL = lipoprotein lipase, SNS = sympathetic nervous system. 
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Markers of inflammation have been examined as potential tools in the prediction of 
cardiovascular events. Of these markers, the acute-phase reactant, high sensitivity C-
reactive protein (hs-CRP), has generated significant interest (Szmitko et al., 2003). 
Emerging evidence suggests that hs-CRP is one of the strongest independent predictors of 
cardiovascular events (Szmitko et al., 2003; Yeh & Willerson, 2003). According to 
LaMonte et al. (2002), elevated hs-CRP is associated with a 2 to 5-fold increase in 
cardiovascular event risk. 
Although hs-CRP has been considered only a biomarker, recent evidence suggests 
that it may directly promote atherosclerosis. According to Szmitko et al. (2003), hs-CRP 
provokes inflammation and-endothelial dysfunction. It appears to reduce transcription of 
endothelial nitric oxide synthase (eNOS), which leads to a diminished release of nitric 
oxide (NO). This in turn reduces protection against vascular injury and inflammation. 
Hs-CRP causes further disruption to endothelial homeostasis by stimulating the release of 
endothelin-1 (ET-1) and interleukin (IL)-6, by upregulating adhesion molecules 
(intracellular adhesion molecule-1, vascular cell adhesion molecule-1, selectins), and by 
stimulating the chemokine monocyte chemoattractant protein-1 (MCP-1). Hs-CRP also 
promotes foam cell formation by facilitating LDL uptake by macrophages (Szmitko et al., 
2003; Yeh & Willerson, 2003). Preliminary observations from Szmitko et al. (2003) also 
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indicate that hs-CRP up-regulates nuclear factor Kappa B (NF- KB), which facilitates 
transcription of several proatherosclerotic genes. Hs-CRPs proatherogenic effects extend 
beyond the endothelium to the vascular smooth muscle (VSM). In concentrations known 
to predict cardiovascular events, hs-CRP demonstrates up-regulation of angiotensin-type 
1 receptors (ATi-R) in vascular SMCs. This augments VSM proliferation, migration, 
reactive oxygen species (ROS) production, and restenosis (Szmitko et al., 2003). 
Observational studies have provided evidence that physical inactivity and low 
cardiorespiratory fitness predict atherosclerotic cardiovascular disease (Blair et al., 1996; 
Ekelund et al., 1988; Lakka et al., 1994, Laukkanen et al., 2001; Lee, Blair, & Jackson, 
1999; Sandvik et al., 1993), while regular physical activity is associated with lower risk 
of coronary heart disease, stroke, and cardiovascular mortality (Erikssen et al. 1998; U.S. 
Department of Health and Human Services). Physical activity may reduce risk, at least in 
part, by modifying the inflammatory process and reducing endothelial dysfunction. 
Recent studies have demonstrated an inverse relationship between inflammatory markers, 
such as hs-CRP, and physical activity (Geffken et al., 2001; Rawsen et al., 2003). Higher 
levels of hs-CRP have also been associated with obesity and insulin resistance, while 
physical activity has been associated with lesser degrees of obesity and insulin resistance. 
Based on these findings many researchers have speculated that physical activity may be 
associated with lower levels of inflammation via its inverse relationship with obesity and 
insulin resistance (LaMonte et al., 2002). 
Obesity and insulin resistance, along with elevated triglycerides, low HDL 
cholesterol, and elevated blood pressure, are characteristics seen in metabolic syndrome 
(Szmitko et al., 2003; Ridker, 2003). Inflammation plays a major role in almost all 
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processes associated with metabolic syndrome. Hs-CRP levels are associated with 
triglycerides, obesity, blood pressure, and fasting glucose (Ridker, 2003; Ridker, Buring, 
Cook, & Rifai, 2003). Ridker (2003) examined the possible interrelationships between 
metabolic syndrome, hs-CRP, and cardiovascular events in participants in the Women's 
Health Study (n = 14,719). The women were aged 45 and older and apparently healthy 
with no prior history of cardiovascular disease or cancer and did not have diabetes at 
baseline. The participants completed data for all components of metabolic syndrome. 
Ridker (2003) found a significant (p-trend < 0.0001) linear relationship between the 
number of metabolic syndrome criteria and hs-CRP level (0.68 mg/L for women who met 
no criteria of the metabolic syndrome to 5.75 mg/L for women who met all 5 criteria). 
Our findings are in support of Ridker's findings. We too found a positive linear 
relationship between hs-CRP and the number of metabolic syndrome characteristics. 
According to Ford, Giles, & Mokdad (2004), physical activity is considered an 
important determinant of the metabolic syndrome. Our results are in support of this 
conclusion. The present study found an inverse relationship between the number of 
metabolic syndrome characteristics and VO2max. In addition we found an inverse 
association between hs-CRP and VO2max, which was in concordance with previous 
research (Church et al., 2002; Mattusch et al., 2000; Smith et al., 1999). It may be that 
high cardiorespiratory fitness (CRF) reduces metabolic syndrome risk factors via a 
reduction in the inflammatory process. 
Regular exercise training appears to lower basal plasma interleukin 
concentrations, such as IL-6, and TNF-a, (Church et al., 2002; Mattusch et al., 2000; 
Smith et al., 1999) which in turn reduces hs-CRP production. According to Ghanim et al. 
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(2004), as transcriptional activity of TNF-a and IL-6 is increased, intranuclear binding of 
the proinflarnmatory transcription factor NF-KB is increased. It may be that exercise 
modulates activation of NF-KB, (Aronson, 2004) thereby reducing TNF-a, IL-6, and CRP. 
This reduction in inflammation may in tun reduce cardiovascular disease risk factors 
seen in metabolic syndrome. 
Inflammation is a common theme connecting all the metabolic syndrome risk 
factors (Black, 2003; Ghanim, et al. 2004; Wexler, et al. 2005). It plays a role in elevated 
blood pressure, dyslipidemia, impaired glucose tolerance, and obesity (Black, 2003; 
Ghanim, et al. 2004; Wexler, et al. 2005). Exercise may reduce these risk factors by 
reducing levels of prioinflammatory cytokines and APPs. Reductions in these 
inflammatory modulators may, for example, reduce blood pressure by improving insulin 
resistance and hyperinsulinemia, by reducing norepinephrine (NE) secretion, and by 
enhancing the vasodilatory effects of nitric oxide (NO) (Wexler, et al. 2005). 
Exercise may also improve dyslipidemia, via reductions in inflammatory 
modulators. Exercise, particularly aerobic exercise, leads to a significant increase in 
HDL cholesterol concentrations and a significant decrease in TG concentrations 
(Rattigan, 2001; LeMura & von Duvillard, 2004). HDL elevation ranges from 2 mg/di to 
8 mg/di or 4-22%, while TG concentrations are reduced by 5 mg/d1 to 38 mg/di or 4-
37%. It is thought that the metabolic demands of exercise produce changes in lipid 
regulatory enzyme activity (LeMura & von Duvillard, 2004). A link between 
lipoprotein lipase (LPL) and increased HDL, particularly HDL2, and decreased TG 
concentrations following exercise has been firmly established (LeMura & von Duvillard, 
2004). LPL activity appears to increase transiently after a single bout of exercise. It 
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reaches a peak approximately 24 hours following exercise (Greiwe, JS, Holloszy J, 
Semenkovich, 2000; LeMura & von Duvillard, 2004). It may be that exercise enhances 
LPL activity via reductions in proinflammatory cytokines. Sympathetically induced 
cytokines depress lipoprotein lipase (LPL) (Black, 2003). In mice, TNF-a and IL-6 have 
been found to reduce LPL activity (Black, 2003). Hence, exercise may reduce 
dyslpidemia, at least in part, via a reduction in inflammation. 
Regular exercise has also been found to improve glycemic control. This too may 
be due to a reduced inflammatory response. Regular exercise has been found to increase 
the expression of GLUT 4 transporters (Greiwe, Holloszy, & Semenkovich, 2000; 
Henriksen, 2002; Raftigan, 2001; Zheng, 2001) and the expression of insulin receptor 
substrate-1 (IRS-1) (Henriksen, 2002). These alterations may be due in part to a 
reduction in TNF-a and IL-6, respectively. Exercise has been found to improve glucose 
tolerance (Rattigan, 2001) and both peripheral and hepatic insulin sensitivity (LeMura & 
von Duvillard, 2004). Improvements in glucose tolerance and insulin sensitivity will 
likely lead to reduced cytokine and APP release, further improving glycemic control. 
It may be that exercise reduces the inflammatory response via a reduction in body 
mass, particularly a reduction in visceral adiposity (Riechman, et al., 2002; Tracy, 2001). 
Numerous researchers have found strong positive associations between hs-CRP and waist 
girth, body fat mass, and visceral adiposity (LaMonte et al., 2002; Rawson et al., 2003; 
Wannamethee et al., 2002). It is now recognized that adipose tissue functions, in part, as 
an immune organ (Wisse, 2004). It secretes many immunomodulatory factors and sends 
inflammatory signals known to cause insulin resistance (Wisse, 2004). Ghanim et al. 
(2004) found increased intranuclear NF-KB binding and increased concentrations of TNF- 
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a and IL-6 in obese subjects. This proinflammatory state may contribute to insulin 
resistance in obese individuals as well as those with metabolic syndrome. Hence, 
exercise may reduce the inflammatory response via a reduction in body mass. 
At this time there are no specific guidelines suggesting the amount of physical 
activity required to reduce inflammation. We found, through Pearson Chi-square 
analysis, that participants engaging in 2-3 hours of exercise per week had hs-CRP levels 
< 2.5 mg/L (p = 0.01817), which is considered low to moderate risk. This finding 
supports the Surgeon General's physical activity recommendations and recommendations 
set by the American College of Sports Medicine (U.S. Department of Health and Human 
Services, 1996; Jakicic, 2001). 
B. Strengths and Limitations 
The present study was based on sound theoretical measurements. Validated 
measures of blood pressure, body mass index, body fat percent, cardiorespiratory fitness, 
and hs-CRP were used. These tools, which have been used for years, increase the 
probability that variables were measured correctly. 
When designing the study a medium effect size was assumed. Power analysis 
was conducted using the statistical software GPOWER (Faul & Erdfelder, 1992). 
Multiple regression analysis was the statistical test used to determine power along with a 
medium effect size (0.15), an alpha of 0.05, and power of 0.80. The total sample size 
needed according to the GPO WER analysis was 131 participants. 
Due to the retrospective nature of this study we had a few limitations. Although 
we had a sufficient number of participants (n = 173), some data was lacking. The 
variable, percent body fat, required over 100 imputations to fill in missing data, hence, 
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we chose not to include it in any analyses. We were, therefore, unable to determine if 
exercise reduced hs-CRP independent of body fat percent. 
The proposed study had a few other possible limitations: (1) reporting bias, (2) 
health habits of regular exercisers, (3) failure to control physical activity prior to blood 
draw, and (4) lack of detailed medication history prior to blood draw. Participants may 
have embellished when filling out the physical activity portion of the PWP. This 
respondent bias could threaten the studies validity. To compensate for this possible bias 
we utilized a second measure of cardiorespiratory fitness level, a Bruce Protocol 
treadmill test. Treadmill test time is highly correlated with measured maximal oxygen 
uptake (Pollock, et al., 1976). Therefore, the present study used an objective laboratory 
measurement of cardiorespiratory fitness that reduces the misclassification bias often 
seen from physical activity self-reports. 
People that exercise regularly may also engage in other positive health behaviors, 
thereby reducing hs-CRP levels. Regular exercisers, for example, may have healthier 
diets than those that do not exercise regularly (Church 2002). This could influence their 
hs-CRP levels. In addition to healthier eating habits, regular exercisers may have 
reduced stress, anxiety, and depression (Petruzzello, Landers, Hatfield, Kubitz, and 
Salazar, 1991; Plante, Unger, Hutchinson, and Faigenbaum, 1990) compared to non-
exercisers. Mental state may influence markers of inflammation (Appels, Bar, Bar, 
Bruggeman, and DeBaets, 2000). According to Black (2003), an acute phase reaction 
may be induced by stress alone. IL-6 is the central mediator of the acute phase reaction 
and it facilitates the production of several acute phase proteins, including hs-CRP. 
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Hence, if a person exercises regularly, thereby reducing stress, he or she may in turn 
decrease hs-CRP levels independently of exercise. 
Intense exercise leads to increased inflammation, hence hs-CRP levels will be 
elevated (Mattusch et al. 2000). The participants were not instructed to refrain from 
exercising prior to the blood draw. If a participant engaged in some form of exercise 
prior to the blood draw hs-CRP levels could have been transiently elevated, thereby 
affecting the study's validity. 
Research has found certain medication influence hs-CRP values. Medications 
such as statins, fibrates, and niacin appear to reduce hs-CRP, while hormone replacement 
therapy appears to elevate hs-CRP levels (Pearson et al., 2003). The PWP does not 




CONCLUSIONS AND RECOMMENDATIONS 
A. Conclusions 
There is increasing evidence that atherosclerosis is a dynamic and progressive 
disease resulting from the combination of inflammation and endothelial dysfunction. 
Advances in basic and experimental science have established that inflammation is 
involved in mediating all stages of this disease from initiation through progression and, 
ultimately, to atherosclerotic plaque complications (Pearson et al., 2003; Libby, Ridker, 
& Maseri, 2002). These new findings not only provide a link between risk factors and 
the mechanisms of atherogenesis, but the connection between inflammation and 
atherosclerosis also provides predictive and prognostic information (Libby, Ridker, & 
Maseri, 2002). Several markers of the inflammatory cascade have been examined as 
potential tools in the prediction of cardiovascular events. Hs-CRP is one of those 
markers and has generated much interest (Szmitko et al., 2003). Emerging evidence 
suggests that hs-CRP is one of the strongest independent predictors of cardiovascular 
events and may play a functional role in the atherosclerotic disease process (Szmitko et 
al., 2003; Yeh & Willerson, 2003). Hs-CRP appears to be even better than low-density 
lipoprotein (LDL) cholesterol at predicting cardiovascular events. This new information 
is profound and is beginning to change the way we screen and manage patients (Yeh & 
Willerson, 2003). 
72 
In addition to hs-CRP's ability to predict cardiovascular events, it also appears to 
add prognostic value to all levels of the metabolic syndrome (Szmitko et al., 2003; 
Ridker, 2003; Festa, D'Agostino, Howard, Mykkanen, Tracy, and Haffner, 2000). In the 
Insulin Resistance Atherosclerosis Study (IRAS), Festa et al. (2000) found that hs-CRP 
levels in non-diabetic subjects increased in a monotonic fashion as the number of 
metabolic disorders increased. According to Ridker (2003), insulin sensitivity and 
impaired fibrinolysis, which are additional factors associated with the metabolic 
syndrome, also appear to be associated with hs-CRP. Hs-CRP also appears to predict 
type 2 diabetes (Ridker, 2003). Risk for developing type 2 diabetes appears to increase 4 
to 6-fold in individuals with hs-CRP levels >3mg/L. These studies support the 
interconnection between atherosclerosis, metabolic disorders, and inflammation. 
Although the mechanisms are unclear, evidence suggests that physical activity 
modifies the inflammatory process. This reduction in inflammation may in turn reduce 
risk factors seen in the metabolic syndrome. At this time only a few studies have 
examined the effects of exercise, hs-CRP, and the metabolic syndrome. Hence, the 
purpose of this study was to confirm and extend existing data regarding the relationship 
between hs-CRP, the metabolic syndrome, and cardiorespiratory fitness (CRF). The 
following is a list of study conclusions: 
(1) Hs-CRP increases linearly with the number of metabolic syndrome 
characteristics. 
(2) Hs-CRP is inversely associated with CRF level. 
(3) CRF level is inversely associated with the number of metabolic syndrome 
characteristics. 
73 
(4) A positive relationship was seen between CRF level and exercise pattern as 
measured by self report. 
(5) Participants engaging in 2-3 hours of physical activity per week had hs-CRP 
levels < 2.5 mg/L placing them in low to moderate risk categories. 
B. Research Recommendations 
More research is clearly needed to assess the relationship between hs-CRP, 
physical activity, metabolic syndrome, and atherosclerosis. A number of questions 
still remain. 
(1) Does the type of physical activity affect hs-CRP level? For example, do 
anaerobic activities such as weight lifting or soccer reduce hs-CRP to the same 
extent as activities that primarily stress the aerobic energy system. 
(2) Does ones enjoyment of the physical activity affect the inflammatory response? 
Psychological states have been associated with increased biomarkers of 
inflammation (Appels, Bar, Bar, Bruggeman, and DeBaets, 2000). Hence, if an 
individual perceives the type of physical activity as unpleasant the inflammatory 
response may be activated rather than reduced. 
(3) Although the present study and others have demonstrated an inverse relationship 
between inflammatory markers, such as hs-CRP, and physical activity, 
mechanisms remain unclear. Several theories exist, however, more research is 
required to determine possible mechanisms. 
(4) It is unclear whether exercise reduces risk factors seen in the metabolic syndrome, 
thereby reducing inflammation or whether exercise reduces inflammation, thereby 
reducing the metabolic syndrome risk factors. More research is required to 
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address the inflammatory response with regard to exercise, hs-CRP, and the 
metabolic syndrome criteria. 
(5) Is the association seen between physical activity and lowered hs-CRP mediated 
by reduced body fat? At this time study results are conflicting regarding the role 
body fat plays in this relationship. It was our intent to examine this controversial 
question, however, we did not have an adequate number of participants with 
percent body fat measured to answer it confidently. 
C. Practice Recommendations 
Current research is beginning to support the theory that hs-CRP is more than just 
a biomarker for CVD. Hence, therapies directed at its reduction appear to be valuable. 
Therapies, such as aspirin or statin-class medications, have been shown to reduce hs-
CRP. Obisesan et al. (2004) stated that statin therapy has been shown to decrease hs-
CRP by 13-17%. Controversy, however, exists as to whether statin therapy is appropriate 
in primary prevention in individuals with high hs-CRP, but normal lipid levels. 
Therefore, lifestyle therapy may be more appropriate in these individuals. 
Physical activity may even reduce hs-CRP to a greater extent than some 
pharmacological therapies. Mattusch et al. (2000) found that nine months of endurance 
training reduced hs-CRP levels by 31% when compared to non-training controls and 
Smith, Dykes, Douglas, Krishnaswamy, and Berk (1999) observed a 35% reduction in hs-
CRP in individuals (n = 43) at high risk of ischemic heart disease following six months of 
supervised exercise training. 
Our findings strengthen the argument that regular physical activity is a valuable 
form of lifestyle therapy. Regular exercise and improved cardiorespiratory fitness level 
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are important means of reducing risk factors associated with atherosclerosis, diabetes, 
and the metabolic syndrome. Our findings support the ATP-III report, which stresses the 
importance of using exercise as first-line therapy for the management of the metabolic 
syndrome (Festa et al., 2000, Tracey, 1997). 
Identifying individuals with elevated hs-CRP and the metabolic syndrome is 
imperative. Once a patient has been identified as having the metabolic syndrome and/or 
elevated hs-CRP, the Preventive Care Specialist should prescribe exercise therapy via 
health education classes and/or individual counseling. Unfortunately, guidelines have not 
been established for the reduction of hs-CRP. 
The present study found that participants engaging in 2-3 hours of exercise per 
week had hs-CRP levels <2.5 mg/L, which is considered low to moderate risk. This 
finding supports the Surgeon General's physical activity recommendations and 
recommendations set by the American College of Sports Medicine (ACSM). The 
Surgeon General's report on physical activity advices people of all ages engage in a 
minimum of 30 minutes of moderate physical activity, such as brisk walking, on most, if 
not all, days of the week to improve health and reduce risk of chronic disease (U.S. 
Department of Health and Human Services, 1996). The ACSM recommends individuals 
attain a minimum of 150 minutes per week of moderate-intensity exercise for health 
benefits (Jakicic, 2001). This moderate amount of physical activity may be ideal for 
reducing inflammation and its associated risk factors. Participating in moderate amounts 
of physical activity along with additional lifestyle therapies, such as stress reduction and 
proper nutrition, will likely reduce inflammation, the metabolic syndrome, and the 
number one killer in the U.S., cardiovascular disease. 
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